299 lines
142 KiB
Text
299 lines
142 KiB
Text
<!DOCTYPE html>
|
|
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" class="no-js no-jr">
|
|
<head>
|
|
<!-- For pinger, set start time and add meta elements. -->
|
|
<script type="text/javascript">var ncbi_startTime = new Date();</script>
|
|
|
|
<!-- Logger begin -->
|
|
<meta name="ncbi_db" content="books">
|
|
<meta name="ncbi_pdid" content="book-toc">
|
|
<meta name="ncbi_acc" content="NBK559938">
|
|
<meta name="ncbi_domain" content="niceng151er6">
|
|
<meta name="ncbi_report" content="reader">
|
|
<meta name="ncbi_type" content="fulltext">
|
|
<meta name="ncbi_objectid" content="">
|
|
<meta name="ncbi_pcid" content="/NBK559938/?report=reader">
|
|
<meta name="ncbi_pagename" content="Deferral of surgery in people having neoadjuvant therapy for rectal cancer - NCBI Bookshelf">
|
|
<meta name="ncbi_bookparttype" content="toc">
|
|
<meta name="ncbi_app" content="bookshelf">
|
|
<!-- Logger end -->
|
|
|
|
<!--component id="Page" label="meta"/-->
|
|
<script type="text/javascript" src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/jr.boots.min.js"> </script><title>Deferral of surgery in people having neoadjuvant therapy for rectal cancer - NCBI Bookshelf</title>
|
|
<meta charset="utf-8">
|
|
<meta name="apple-mobile-web-app-capable" content="no">
|
|
<meta name="viewport" content="initial-scale=1,minimum-scale=1,maximum-scale=1,user-scalable=no">
|
|
<meta name="jr-col-layout" content="1">
|
|
<meta name="robots" content="INDEX,FOLLOW,NOARCHIVE,NOIMAGEINDEX">
|
|
<meta name="author" content="National Guideline Alliance (UK)">
|
|
<meta name="citation_title" content="Deferral of surgery in people having neoadjuvant therapy for rectal cancer">
|
|
<meta name="citation_publisher" content="National Institute for Health and Care Excellence (NICE)">
|
|
<meta name="citation_date" content="2020/01">
|
|
<meta name="citation_author" content="National Guideline Alliance (UK)">
|
|
<meta name="citation_pmid" content="32730007">
|
|
<meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK559938/">
|
|
<link rel="schema.DC" href="http://purl.org/DC/elements/1.0/">
|
|
<meta name="DC.Title" content="Deferral of surgery in people having neoadjuvant therapy for rectal cancer">
|
|
<meta name="DC.Type" content="Text">
|
|
<meta name="DC.Publisher" content="National Institute for Health and Care Excellence (NICE)">
|
|
<meta name="DC.Contributor" content="National Guideline Alliance (UK)">
|
|
<meta name="DC.Date" content="2020/01">
|
|
<meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK559938/">
|
|
<meta name="og:title" content="Deferral of surgery in people having neoadjuvant therapy for rectal cancer">
|
|
<meta name="og:type" content="book">
|
|
<meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK559938/">
|
|
<meta name="og:site_name" content="NCBI Bookshelf">
|
|
<meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-niceng151er6-lrg.png">
|
|
<meta name="twitter:card" content="summary">
|
|
<meta name="twitter:site" content="@ncbibooks">
|
|
<meta name="bk-non-canon-loc" content="/books/n/niceng151er6/toc/?report=reader">
|
|
<link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK559938/">
|
|
<link href="https://fonts.googleapis.com/css?family=Archivo+Narrow:400,700,400italic,700italic&subset=latin" rel="stylesheet" type="text/css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/jatsreader/ptpmc_3.22/css/libs.min.css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/jatsreader/ptpmc_3.22/css/jr.min.css">
|
|
<meta name="format-detection" content="telephone=no">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books.min.css" type="text/css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css//books_print.min.css" type="text/css" media="print">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books_reader.min.css" type="text/css">
|
|
<style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace} .first-line-outdent .bk_ref {display: inline} .body-content h2, .body-content .h2 {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list .graphic {display:inline-block !important} .temp-labeled-list img{width:100%}</style>
|
|
|
|
<link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico">
|
|
<meta name="ncbi_phid" content="CE8D87087D72F5410000000000020002.m_5">
|
|
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/css/3852956/3849091.css"></head>
|
|
<body>
|
|
<!-- Book content! -->
|
|
|
|
|
|
<div id="jr" data-jr-path="/corehtml/pmc/jatsreader/ptpmc_3.22/"><div class="jr-unsupported"><table class="modal"><tr><td><span class="attn inline-block"></span><br />Your browser does not support the NLM PubReader view.<br />Go to <a href="/pmc/about/pr-browsers/">this page</a> to see a list of supported browsers<br />or return to the <br /><a href="/books/NBK559938/?report=classic">regular view</a>.</td></tr></table></div><div id="jr-ui" class="hidden"><nav id="jr-head"><div class="flexh tb"><div id="jr-tb1"><a id="jr-links-sw" class="hidden" title="Links"><svg xmlns="http://www.w3.org/2000/svg" version="1.1" x="0px" y="0px" viewBox="0 0 70.6 85.3" style="enable-background:new 0 0 70.6 85.3;vertical-align:middle" xml:space="preserve" width="24" height="24">
|
|
<style type="text/css">.st0{fill:#939598;}</style>
|
|
<g>
|
|
<path class="st0" d="M36,0C12.8,2.2-22.4,14.6,19.6,32.5C40.7,41.4-30.6,14,35.9,9.8"></path>
|
|
<path class="st0" d="M34.5,85.3c23.2-2.2,58.4-14.6,16.4-32.5c-21.1-8.9,50.2,18.5-16.3,22.7"></path>
|
|
<path class="st0" d="M34.7,37.1c66.5-4.2-4.8-31.6,16.3-22.7c42.1,17.9,6.9,30.3-16.4,32.5h1.7c-66.2,4.4,4.8,31.6-16.3,22.7 c-42.1-17.9-6.9-30.3,16.4-32.5"></path>
|
|
</g>
|
|
</svg> Books</a></div><div class="jr-rhead f1 flexh"></div><div id="jr-tb2"><a id="jr-bkhelp-sw" class="btn wsprkl hidden" title="Help with NLM PubReader">?</a><a id="jr-help-sw" class="btn wsprkl hidden" title="Settings and typography in NLM PubReader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512" preserveAspectRatio="none"><path d="M462,283.742v-55.485l-29.981-10.662c-11.431-4.065-20.628-12.794-25.274-24.001 c-0.002-0.004-0.004-0.009-0.006-0.013c-4.659-11.235-4.333-23.918,0.889-34.903l13.653-28.724l-39.234-39.234l-28.72,13.652 c-10.979,5.219-23.68,5.546-34.908,0.889c-0.005-0.002-0.01-0.003-0.014-0.005c-11.215-4.65-19.933-13.834-24-25.273L283.741,50 h-55.484l-10.662,29.981c-4.065,11.431-12.794,20.627-24.001,25.274c-0.005,0.002-0.009,0.004-0.014,0.005 c-11.235,4.66-23.919,4.333-34.905-0.889l-28.723-13.653l-39.234,39.234l13.653,28.721c5.219,10.979,5.545,23.681,0.889,34.91 c-0.002,0.004-0.004,0.009-0.006,0.013c-4.649,11.214-13.834,19.931-25.271,23.998L50,228.257v55.485l29.98,10.661 c11.431,4.065,20.627,12.794,25.274,24c0.002,0.005,0.003,0.01,0.005,0.014c4.66,11.236,4.334,23.921-0.888,34.906l-13.654,28.723 l39.234,39.234l28.721-13.652c10.979-5.219,23.681-5.546,34.909-0.889c0.005,0.002,0.01,0.004,0.014,0.006 c11.214,4.649,19.93,13.833,23.998,25.271L228.257,462h55.484l10.595-29.79c4.103-11.538,12.908-20.824,24.216-25.525 c0.005-0.002,0.009-0.004,0.014-0.006c11.127-4.628,23.694-4.311,34.578,0.863l28.902,13.738l39.234-39.234l-13.66-28.737 c-5.214-10.969-5.539-23.659-0.886-34.877c0.002-0.005,0.004-0.009,0.006-0.014c4.654-11.225,13.848-19.949,25.297-24.021 L462,283.742z M256,331.546c-41.724,0-75.548-33.823-75.548-75.546s33.824-75.547,75.548-75.547 c41.723,0,75.546,33.824,75.546,75.547S297.723,331.546,256,331.546z"></path></svg></a><a id="jr-fip-sw" class="btn wsprkl hidden" title="Find"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 550 600" preserveAspectRatio="none"><path fill="none" stroke="#000" stroke-width="36" stroke-linecap="round" style="fill:#FFF" d="m320,350a153,153 0 1,0-2,2l170,170m-91-117 110,110-26,26-110-110"></path></svg></a><a id="jr-cmap-sw" class="btn wsprkl hidden" title="Table of Contents"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M20,20h10v8H20V20zM36,20h44v8H36V20zM20,37.33h10v8H20V37.33zM36,37.33h44v8H36V37.33zM20,54.66h10v8H20V54.66zM36,54.66h44v8H36V54.66zM20,72h10v8 H20V72zM36,72h44v8H36V72z"></path></svg></a></div></div></nav><nav id="jr-dash" class="noselect"><nav id="jr-dash" class="noselect"><div id="jr-pi" class="hidden"><a id="jr-pi-prev" class="hidden" title="Previous page"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a><div class="pginfo">Page <i class="jr-pg-pn">0</i> of <i class="jr-pg-lp">0</i></div><a id="jr-pi-next" class="hidden" title="Next page"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div><div id="jr-is-tb"><a id="jr-is-sw" class="btn wsprkl hidden" title="Switch between Figures/Tables strip and Progress bar"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><rect x="10" y="40" width="20" height="20"></rect><rect x="40" y="40" width="20" height="20"></rect><rect x="70" y="40" width="20" height="20"></rect></svg></a></div><nav id="jr-istrip" class="istrip hidden"><a id="jr-is-prev" href="#" class="hidden" title="Previous"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M80,40 60,65 80,90 70,90 50,65 70,40z M50,40 30,65 50,90 40,90 20,65 40,40z"></path><text x="35" y="25" textLength="60" style="font-size:25px">Prev</text></svg></a><a id="jr-is-next" href="#" class="hidden" title="Next"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M20,40 40,65 20,90 30,90 50,65 30,40z M50,40 70,65 50,90 60,90 80,65 60,40z"></path><text x="15" y="25" textLength="60" style="font-size:25px">Next</text></svg></a></nav><nav id="jr-progress"></nav></nav></nav><aside id="jr-links-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">NCBI Bookshelf</div></div><div class="cnt lol f1"><a href="/books/">Home</a><a href="/books/browse/">Browse All Titles</a><a class="btn share" target="_blank" rel="noopener noreferrer" href="https://www.facebook.com/sharer/sharer.php?u=https://www.ncbi.nlm.nih.gov/books/NBK559938/"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 33 33" style="vertical-align:middle" width="24" height="24" preserveAspectRatio="none"><g><path d="M 17.996,32L 12,32 L 12,16 l-4,0 l0-5.514 l 4-0.002l-0.006-3.248C 11.993,2.737, 13.213,0, 18.512,0l 4.412,0 l0,5.515 l-2.757,0 c-2.063,0-2.163,0.77-2.163,2.209l-0.008,2.76l 4.959,0 l-0.585,5.514L 18,16L 17.996,32z"></path></g></svg> Share on Facebook</a><a class="btn share" target="_blank" rel="noopener noreferrer" href="https://twitter.com/intent/tweet?url=https://www.ncbi.nlm.nih.gov/books/NBK559938/&text=Deferral%20of%20surgery%20in%20people%20having%20neoadjuvant%20therapy%20for%20rectal%20cancer"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 33 33" style="vertical-align:middle" width="24" height="24"><g><path d="M 32,6.076c-1.177,0.522-2.443,0.875-3.771,1.034c 1.355-0.813, 2.396-2.099, 2.887-3.632 c-1.269,0.752-2.674,1.299-4.169,1.593c-1.198-1.276-2.904-2.073-4.792-2.073c-3.626,0-6.565,2.939-6.565,6.565 c0,0.515, 0.058,1.016, 0.17,1.496c-5.456-0.274-10.294-2.888-13.532-6.86c-0.565,0.97-0.889,2.097-0.889,3.301 c0,2.278, 1.159,4.287, 2.921,5.465c-1.076-0.034-2.088-0.329-2.974-0.821c-0.001,0.027-0.001,0.055-0.001,0.083 c0,3.181, 2.263,5.834, 5.266,6.438c-0.551,0.15-1.131,0.23-1.73,0.23c-0.423,0-0.834-0.041-1.235-0.118 c 0.836,2.608, 3.26,4.506, 6.133,4.559c-2.247,1.761-5.078,2.81-8.154,2.81c-0.53,0-1.052-0.031-1.566-0.092 c 2.905,1.863, 6.356,2.95, 10.064,2.95c 12.076,0, 18.679-10.004, 18.679-18.68c0-0.285-0.006-0.568-0.019-0.849 C 30.007,8.548, 31.12,7.392, 32,6.076z"></path></g></svg> Share on Twitter</a></div></aside><aside id="jr-cmap-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">In Page Navigation</div></div><div class="cnt lol f1"><a href="/books/n/niceercollect/?report=reader">NICE Evidence Reviews Collection</a><a class="current">Title Information</a></div></aside><aside id="jr-help-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Settings</div></div><div class="cnt f1"><div id="jr-typo-p" class="typo"><div><a class="sf btn wsprkl">A-</a><a class="lf btn wsprkl">A+</a></div><div><a class="bcol-auto btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 200 100" preserveAspectRatio="none"><text x="10" y="70" style="font-size:60px;font-family: Trebuchet MS, ArialMT, Arial, sans-serif" textLength="180">AUTO</text></svg></a><a class="bcol-1 btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M15,25 85,25zM15,40 85,40zM15,55 85,55zM15,70 85,70z"></path></svg></a><a class="bcol-2 btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M5,25 45,25z M55,25 95,25zM5,40 45,40z M55,40 95,40zM5,55 45,55z M55,55 95,55zM5,70 45,70z M55,70 95,70z"></path></svg></a></div></div><div class="lol"><a class="" href="/books/NBK559938/?report=classic">Switch to classic view</a><a href="/books/n/niceng151er6/pdf/">PDF (419K)</a><a href="/books/n/niceng151er6/toc/?report=printable">Print View</a></div></div></aside><aside id="jr-bkhelp-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Help</div></div><div class="cnt f1 lol"><a id="jr-helpobj-sw" data-path="/corehtml/pmc/jatsreader/ptpmc_3.22/" data-href="/corehtml/pmc/jatsreader/ptpmc_3.22/img/bookshelf/help.xml" href="">Help</a><a href="mailto:info@ncbi.nlm.nih.gov?subject=PubReader%20feedback%20%2F%20NBK559938%20%2F%20sid%3ACE8B5AF87C7FFCB1_0191SID%20%2F%20phid%3ACE8D87087D72F5410000000000020002.4">Send us feedback</a><a id="jr-about-sw" data-path="/corehtml/pmc/jatsreader/ptpmc_3.22/" data-href="/corehtml/pmc/jatsreader/ptpmc_3.22/img/bookshelf/about.xml" href="">About PubReader</a></div></aside><aside id="jr-objectbox" class="thidden hidden"><div class="jr-objectbox-close wsprkl">✘</div><div class="jr-objectbox-inner cnt"><div class="jr-objectbox-drawer"></div></div></aside><nav id="jr-pm-left" class="hidden"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 800" preserveAspectRatio="none"><text font-stretch="ultra-condensed" x="800" y="-15" text-anchor="end" transform="rotate(90)" font-size="18" letter-spacing=".1em">Previous Page</text></svg></nav><nav id="jr-pm-right" class="hidden"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 800" preserveAspectRatio="none"><text font-stretch="ultra-condensed" x="800" y="-15" text-anchor="end" transform="rotate(90)" font-size="18" letter-spacing=".1em">Next Page</text></svg></nav><nav id="jr-fip" class="hidden"><nav id="jr-fip-term-p"><input type="search" placeholder="search this page" id="jr-fip-term" autocorrect="off" autocomplete="off" /><a id="jr-fip-mg" class="wsprkl btn" title="Find"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 550 600" preserveAspectRatio="none"><path fill="none" stroke="#000" stroke-width="36" stroke-linecap="round" style="fill:#FFF" d="m320,350a153,153 0 1,0-2,2l170,170m-91-117 110,110-26,26-110-110"></path></svg></a><a id="jr-fip-done" class="wsprkl btn" title="Dismiss find">✘</a></nav><nav id="jr-fip-info-p"><a id="jr-fip-prev" class="wsprkl btn" title="Jump to previuos match">◀</a><button id="jr-fip-matches">no matches yet</button><a id="jr-fip-next" class="wsprkl btn" title="Jump to next match">▶</a></nav></nav></div><div id="jr-epub-interstitial" class="hidden"></div><div id="jr-content"><article data-type="main"><div class="main-content lit-style"><div class="fm-sec bkr_bottom_sep"><div class="bkr_thumb"><a href="https://www.nice.org.uk" title="National Institute for Health and Care Excellence (NICE)" class="img_link icnblk_img" ref="pagearea=logo&targetsite=external&targetcat=link&targettype=publisher"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-niceng151er6-lrg.png" alt="Cover of Deferral of surgery in people having neoadjuvant therapy for rectal cancer" /></a></div><div class="bkr_bib"><h1 id="_NBK559938_"><span itemprop="name">Deferral of surgery in people having neoadjuvant therapy for rectal cancer</span></h1><div class="subtitle">Colorectal cancer (update)</div><p><b>Evidence review C4</b></p><p><i>NICE Guideline, No. 151</i></p><p class="contrib-group"><h4>Authors</h4><span itemprop="author">National Guideline Alliance (UK)</span>.</p><div class="half_rhythm">London: <a href="https://www.nice.org.uk" ref="pagearea=meta&targetsite=external&targetcat=link&targettype=publisher"><span itemprop="publisher">National Institute for Health and Care Excellence (NICE)</span></a>; <span itemprop="datePublished">2020 Jan</span>.<div class="small">ISBN-13: <span itemprop="isbn">978-1-4731-3657-1</span></div></div><div><a href="/books/about/copyright/">Copyright</a> © NICE 2020.</div></div><div class="bkr_clear"></div></div><div id="ch6.s1"><h2 id="_ch6_s1_">Deferral of surgery in people having neoadjuvant therapy for rectal cancer</h2><p>This evidence review supports <a href="/books/n/niceng151/?report=reader" class="toc-item">recommendations 1.3.4</a> to <a href="/books/n/niceng151/?report=reader" class="toc-item">1.3.5</a>.</p><div id="ch6.s1.1"><h3>Review question</h3><p>Which people having neoadjuvant radiotherapy or chemoradiotherapy for rectal cancer do not need surgery?</p><div id="ch6.s1.1.1"><h4>Introduction</h4><p>People whose rectal cancer shows a complete clinical response to neoadjuvant therapy may choose to defer surgery, thereby avoiding the risk of surgical morbidity. However, despite having a complete clinical response some patients following such a watch and wait approach will experience locoregional recurrence or progression. This review question aimed to identify prognostic factors that predict recurrence and survival to better select people for watch and wait management.</p></div><div id="ch6.s1.1.2"><h4>Summary of protocol</h4><p>Please see <a class="figpopup" href="/books/NBK559938/table/ch6.tab1/?report=objectonly" target="object" rid-figpopup="figch6tab1" rid-ob="figobch6tab1">Table 1</a> for a summary of the population, prognostic factors, and outcomes (PPO) characteristics of this review.</p><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figch6tab1"><a href="/books/NBK559938/table/ch6.tab1/?report=objectonly" target="object" title="Table 1" class="img_link icnblk_img figpopup" rid-figpopup="figch6tab1" rid-ob="figobch6tab1"><img class="small-thumb" src="/books/NBK559938/table/ch6.tab1/?report=thumb" src-large="/books/NBK559938/table/ch6.tab1/?report=previmg" alt="Table 1. Summary of the protocol (PFO table)." /></a><div class="icnblk_cntnt"><h4 id="ch6.tab1"><a href="/books/NBK559938/table/ch6.tab1/?report=objectonly" target="object" rid-ob="figobch6tab1">Table 1</a></h4><p class="float-caption no_bottom_margin">Summary of the protocol (PFO table). </p></div></div><p>For full details see the review protocol in <a href="#ch6.appa">appendix A</a></p></div><div id="ch6.s1.1.3"><h4>Methods and process</h4><p>This evidence review was developed using the methods and process described in <a href="https://www.nice.org.uk/process/pmg20/chapter/introduction-and-overview" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Developing NICE guidelines: the manual</a>
|
|
<u>2014</u>. Methods specific to this review question are described in the review protocol in <a href="#ch6.appa">appendix A</a>.</p><p>Declarations of interest were recorded according to NICE’s 2014 conflicts of interest policy until 31 March 2018. From 1 April 2018, declarations of interest were recorded according to NICE’s 2018 <a href="https://www.nice.org.uk/about/who-we-are/policies-and-procedures" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">conflicts of interest policy</a>. Those interests declared until April 2018 were reclassified according to NICE’s 2018 conflicts of interest policy (see Register of Interests).</p></div><div id="ch6.s1.1.4"><h4>Clinical evidence</h4><div id="ch6.s1.1.4.1"><h5>Included studies</h5><p>A systematic review of the clinical literature was conducted but no studies were identified which were applicable to this review question.</p><p>See the literature search strategy in <a href="#ch6.appb">appendix B</a> and study selection flow chart in <a href="#ch6.appc">appendix C</a>.</p></div><div id="ch6.s1.1.4.2"><h5>Excluded studies</h5><p>No studies were identified which were applicable to this review question.</p></div></div><div id="ch6.s1.1.5"><h4>Summary of clinical studies included in the evidence review</h4><p>No studies were identified which were applicable to this review question (and so there are no evidence tables in <a href="#ch6.appd">appendix D</a>). No meta-analysis was undertaken for this review (and so there are no forest plots in <a href="#ch6.appe">appendix E</a>).</p></div><div id="ch6.s1.1.6"><h4>Quality assessment of clinical outcomes included in the evidence review</h4><p>No studies were identified which were applicable to this review question.</p></div><div id="ch6.s1.1.7"><h4>Economic evidence</h4><div id="ch6.s1.1.7.1"><h5>Included studies</h5><p>One relevant study was identified in a literature review of published cost-effectiveness analyses on this topic (<a class="bibr" href="#ch6.s1.1.ref1" rid="ch6.s1.1.ref1">Rao 2017</a>; see <a href="#ch6.apph">appendix H</a> and <a href="#ch6.appi">appendix I</a> for summary and full evidence tables). The study considered the cost-effectiveness of watch and wait in comparison to radical surgery for patients with rectal cancer after a clinical complete response following chemoradiotherapy. The study considered three patient groups; 60 year old male cohort with no co-morbidities, 80 year old male cohort with no co-morbidities and 80 year old male cohort with significant co-morbidities.</p><p>The analysis was a cost-utility analysis measuring effectiveness in terms of quality adjusted life years (QALYs).</p></div><div id="ch6.s1.1.7.2"><h5>Excluded studies</h5><p>A global search of economic evidence was undertaken for all review questions in this guideline. See Supplement 2 for further information.</p></div></div><div id="ch6.s1.1.8"><h4>Summary of studies included in the economic evidence review</h4><p>The base case results of <a class="bibr" href="#ch6.s1.1.ref1" rid="ch6.s1.1.ref1">Rao 2017</a> suggest that watch and wait was found to be more effective and more costly than radical surgery in all modelled patient groups. The strategy was therefore dominant in all patient groups.</p><p>Uncertainty was assessed using deterministic and probabilistic sensitivity analysis. Results were found to be sensitive to relative recurrence rates after watch and wait (WW) and radical surgery as well as changes in the quality of life (QoL) reduction with radical surgery. It was also found that the model became sensitive to changes in perioperative mortality when the QoL benefit of WW was reduced. In probabilistic sensitivity analysis watch and wait was found to have a 74%, 85% and 90% probability of being cost-effective in the 60 year old male cohort, 80 year old male cohort with no co-morbidities and 80 year old male cohort with significant co-morbidities, respectively.</p><p>Despite being a UK study considering the NHS perspective, the study was considered to be only partially applicable. This is because it doesn’t directly address the review question posed in the guideline (but it is partially addressed by the different subgroups considered in the analysis). Whilst the study meets most of the requirements of an adequate economic evaluation (see Developing NICE guidelines: <a href="#ch6.apph">appendix H</a>), it was deemed to have some potentially serious limitations. Most notably, a key aspect of the analysis is the QoL gain with watch and wait and this is based on QoL values from another disease area (prostate cancer).</p></div><div id="ch6.s1.1.9"><h4>Economic model</h4><p>No economic modelling was undertaken for this review because the committee agreed that other topics were higher priorities for economic evaluation.</p></div><div id="ch6.s1.1.10"><h4>Evidence statements</h4><div id="ch6.s1.1.10.1"><h5>Clinical evidence statements</h5><p>No clinical evidence was identified which was applicable to this review question.</p></div><div id="ch6.s1.1.10.2"><h5>Economic evidence statements</h5><p>One relevant study was identified in the literature review of published cost effectiveness analyses on this topic (<a class="bibr" href="#ch6.s1.1.ref1" rid="ch6.s1.1.ref1">Rao 2017</a>). This was a cost utility study, partially applicable to the decision problem with potentially serious methodological limitations, comparing radical surgery to a ‘watch and wait’ strategy involving outpatient imaging and monitoring in male patients who had had a complete response to neoadjuvant therapy and were suitable for surgery for rectal cancer. ‘Watch and wait’ was the dominant intervention in all subgroups leading to a reduction in both costs (ranging from £6,274 to £8,095) and an increase in QALYs (ranging from 0.56 to 0.72). Probabilistic sensitivity analysis estimated the probability of ‘watch and wait’ being cost effective when QALYs are valued at £20,000 each, is over 74% for all sub-groups.</p></div></div><div id="ch6.s1.1.11"><h4>The committee’s discussion of the evidence</h4><div id="ch6.s1.1.11.1"><h5>Interpreting the evidence</h5><div id="ch6.s1.1.11.1.1"><h5>The outcomes that matter most</h5><p>Locoregional progression or recurrence was a critical outcome because it typically leads to further treatment with associated treatment related adverse effects. Overall survival and disease free survival were also critical outcomes because a watch and wait strategy (with deferred surgery) would only be safe if it did not impact survival. Organ preservation rate was an important outcome because organ preservation avoids the morbidity and functional consequences of major surgery.</p></div><div id="ch6.s1.1.11.1.2"><h5>The quality of the evidence</h5><p>No evidence was identified which was applicable to this review question.</p></div><div id="ch6.s1.1.11.1.3"><h5>Benefits and harms</h5><p>Surgery is the gold standard treatment for rectal cancer. However, some people whose rectal cancer shows a complete clinical response to neoadjuvant therapy wish to defer surgery and opt for an organ preserving ‘watch and wait’ strategy instead. The committee acknowledged that while the watch and wait strategy avoids harms due to surgery around one third will experience local regrowth of their tumour and need salvage surgery. Any local regrowth needs to be detected and treated to avoid disease progression, however this involves a surveillance protocol with repeated examinations which may be inconvenient for some patients.</p><p>No evidence was identified on the prognostic factors which could predict recurrence or survival, therefore, there is no evidence to help identify groups of patients for whom deferral of surgery would or would not be appropriate. The committee also recognised the lack of agreed definition of complete clinical or radiological response bringing further uncertainty to who might be candidates for deferral of surgery. For these reasons the committee could not recommend deferral of surgery.</p><p>The committee agreed that if a person wishes to defer surgery, they should be informed that there is no evidence to help define for whom deferral might be appropriate and that there is a risk of recurrence. If a person still chooses to defer surgery, deferral should only happen in the context of a clinical trial or a national registry where patients are closely monitored in order to detect and treat any local regrowth of their tumour. Patients should be encouraged to enter a clinical trial (for example on going trials OPERA or TRIGGER) and data collection via a national registry should be ensured. This would generate evidence in the future to help define groups that might benefit from deferral of surgery.</p></div></div><div id="ch6.s1.1.11.2"><h5>Cost effectiveness and resource use</h5><p>One relevant study was identified in the literature review of published cost effectiveness analyses on this topic (<a class="bibr" href="#ch6.s1.1.ref1" rid="ch6.s1.1.ref1">Rao 2017</a>). This was a cost utility study comparing radial surgery to a ‘watch and wait’ strategy involving outpatient imaging and monitoring in male patients who had had a complete response to neoadjuvant therapy and were suitable for surgery for rectal cancer. Three different patient groups were considered - 60 year olds with no comorbidities, 80 year olds with no comorbidities and 80 year olds with significant comorbidities. The model was a decision tree and markov model informed by previous estimates from the literature. All costs were taken from NHS reference costs and the analysis took a NHS & PSS perspective.</p><p>‘Watch and wait’ was the dominant intervention in all subgroups leading to a reduction in both costs (ranging from £6,274 to £8,095) and an increase in QALYs (ranging from 0.56 to 0.72). Deterministic sensitivity analysis was conducted in two ways. Alternative scenarios to the base case were explored which involved applying National Comprehensive Cancer Network (NCCN) protocols for follow-up, correlated cost parameters or doubling all costs. Watch and wait remained dominant under all these alternate assumptions.</p><p>It was found that the results of the model were sensitive to relative recurrence rates after watch and wait and radical surgery as well as changes in the quality of life reduction with radical surgery. It was also found that the model became sensitive to changes in perioperative mortality when the quality of life benefit of ‘watch and wait’ was reduced. The model was not found to be sensitive to variations in baseline mortality and operative mortality or individual cost parameters. Probabilistic sensitivity analysis estimated the probability of ‘watch and wait’ being cost effective at a £20,000 per QALY threshold at over 74% for all sub-groups.</p><p>Despite being a recent UK cost effectiveness study it was deemed only partially applicable to the review questions as it did not directly address the review question posed in the guideline. The question was only partially addressed by the different subgroups considered. It was also deemed to have some potentially serious methodological limitations. Most notably, a key aspect of the analysis is the quality of life gain with ‘watch and wait’ and this is based on values from another disease area (prostate cancer).</p><p>The committee found the study to be of limited value in addressing the review question because it didn’t consider the patient factors which were of most interest.</p></div><div id="ch6.s1.1.11.3"><h5>Other factors the committee took into account</h5><p>The committee were aware of an international registry of patients with rectal cancer managed by a watch and wait strategy after complete clinical response to neoadjuvant therapy. Only a multicentre project like this is likely to collect sufficient patient numbers to answer the question of who is best suited to a watch and wait strategy. Also ongoing trials such as OPERA and TRIGGER may generate evidence in the future on who is most suitable for deferral of surgery. For this reason they chose not to make a research recommendation for a new trial.</p></div></div><div id="ch6.rl.r1"><h4>References</h4><ul class="simple-list"><li class="half_rhythm"><p><div class="bk_ref" id="ch6.s1.1.ref1"><p id="p-62">
|
|
<strong>Rao 2017</strong>
|
|
</p>Rao
|
|
C, Sun Myint
|
|
A, Athanasiou
|
|
T, et al. (2017) Avoiding Radical Surgery in Elderly Patients With Rectal Cancer Is Cost-Effective. Diseases of the Colon and Rectum
|
|
60(1): 30–42 [<a href="https://pubmed.ncbi.nlm.nih.gov/27926555" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 27926555</span></a>]</div></p></li></ul></div></div></div><div id="appendixesappgroup6"><h2 id="_appendixesappgroup6_">Appendices</h2><div id="ch6.appa"><h3>Appendix A. Review protocol</h3><div id="ch6.appa.s1"><h4>Review protocol for review question: Which people having neoadjuvant radiotherapy or chemoradiotherapy for rectal cancer do not need surgery?</h4><p id="ch6.appa.tab1"><a href="/books/NBK559938/table/ch6.appa.tab1/?report=objectonly" target="object" rid-ob="figobch6appatab1" class="figpopup">Table 2. Review protocol for deferral of surgery in people having neoadjuvant therapy for rectal cancer</a></p></div></div><div id="ch6.appb"><h3>Appendix B. Literature search strategies</h3><div id="ch6.appb.s1"><h4>Literature search strategies for review question: Which people having neoadjuvant radiotherapy or chemoradiotherapy for rectal cancer do not need surgery?</h4><div id="ch6.appb.s1.1"><h5>Database: Embase/Medline</h5><p>Last searched on: 12/02/2019</p><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figch6appbtab1"><a href="/books/NBK559938/table/ch6.appb.tab1/?report=objectonly" target="object" title="Table" class="img_link icnblk_img figpopup" rid-figpopup="figch6appbtab1" rid-ob="figobch6appbtab1"><img class="small-thumb" src="/books/NBK559938/table/ch6.appb.tab1/?report=thumb" src-large="/books/NBK559938/table/ch6.appb.tab1/?report=previmg" alt="Image " /></a><div class="icnblk_cntnt"><h4 id="ch6.appb.tab1"><a href="/books/NBK559938/table/ch6.appb.tab1/?report=objectonly" target="object" rid-ob="figobch6appbtab1">Table</a></h4></div></div></div><div id="ch6.appb.s1.2"><h5>Database: Cochrane Library</h5><p>Last searched on: 12/02/2019</p><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figch6appbtab2"><a href="/books/NBK559938/table/ch6.appb.tab2/?report=objectonly" target="object" title="Table" class="img_link icnblk_img figpopup" rid-figpopup="figch6appbtab2" rid-ob="figobch6appbtab2"><img class="small-thumb" src="/books/NBK559938/table/ch6.appb.tab2/?report=thumb" src-large="/books/NBK559938/table/ch6.appb.tab2/?report=previmg" alt="Image " /></a><div class="icnblk_cntnt"><h4 id="ch6.appb.tab2"><a href="/books/NBK559938/table/ch6.appb.tab2/?report=objectonly" target="object" rid-ob="figobch6appbtab2">Table</a></h4></div></div></div></div></div><div id="ch6.appc"><h3>Appendix C. Clinical evidence study selection</h3><div id="ch6.appc.s1"><h4>Clinical study selection for review question: Which people having neoadjuvant radiotherapy or chemoradiotherapy for rectal cancer do not need surgery?</h4><p id="ch6.appc.fig1"><a href="/books/NBK559938/figure/ch6.appc.fig1/?report=objectonly" target="object" rid-ob="figobch6appcfig1" class="figpopup">Figure 1. Study selection flow chart</a></p></div></div><div id="ch6.appd"><h3>Appendix D. Clinical evidence tables</h3><div id="ch6.appd.s1"><h4>Clinical evidence tables for review question: Which people having neoadjuvant radiotherapy or chemoradiotherapy for rectal cancer do not need surgery?</h4><p>No clinical evidence was identified which was applicable to this review question.</p></div></div><div id="ch6.appe"><h3>Appendix E. Forest plots</h3><div id="ch6.appe.s1"><h4>Forest plots for review question: Which people having neoadjuvant radiotherapy or chemoradiotherapy for rectal cancer do not need surgery?</h4><p>No clinical evidence was identified which was applicable to this review question.</p></div></div><div id="ch6.appf"><h3>Appendix F. GRADE tables</h3><div id="ch6.appf.s1"><h4>GRADE tables for review question: Which people having neoadjuvant radiotherapy or chemoradiotherapy for rectal cancer do not need surgery?</h4><p>No clinical evidence was identified which was applicable to this review question.</p></div></div><div id="ch6.appg"><h3>Appendix G. Economic evidence study selection</h3><div id="ch6.appg.s1"><h4>Economic evidence study selection for review question: Which people having neoadjuvant radiotherapy or chemoradiotherapy for rectal cancer do not need surgery?</h4><p>A global search of economic evidence was undertaken for all review questions in this guideline. See Supplement 2 for further information.</p></div></div><div id="ch6.apph"><h3>Appendix H. Economic evidence tables</h3><div id="ch6.apph.s1"><h4>Economic evidence tables for review question: Which people having neoadjuvant radiotherapy or chemoradiotherapy for rectal cancer do not need surgery?</h4><p id="ch6.apph.et1"><a href="/books/NBK559938/bin/ch6-apph-et1.pdf" class="bk_dwnld_icn bk_dwnld_pdf">Table 3. Economic evidence tables for deferral of surgery in people having neoadjuvant therapy for rectal cancer</a><span class="small"> (PDF, 167K)</span></p></div></div><div id="ch6.appi"><h3>Appendix I. Economic evidence profiles</h3><div id="ch6.appi.s1"><h4>Economic evidence profiles for review question: Which people having neoadjuvant radiotherapy or chemoradiotherapy for rectal cancer do not need surgery?</h4><p id="ch6.appi.et1"><a href="/books/NBK559938/bin/ch6-appi-et1.pdf" class="bk_dwnld_icn bk_dwnld_pdf">Table 4. Economic evidence profiles for people having neoadjuvant radiotherapy or chemoradiotherapy for rectal cancer do not need surgery</a><span class="small"> (PDF, 148K)</span></p></div></div><div id="ch6.appj"><h3>Appendix J. Economic analysis</h3><div id="ch6.appj.s1"><h4>Economic evidence analysis for review question: Which people having neoadjuvant radiotherapy or chemoradiotherapy for rectal cancer do not need surgery?</h4><p>No economic analysis was conducted for this review question.</p></div></div><div id="ch6.appk"><h3>Appendix K. Excluded studies</h3><div id="ch6.appk.s1"><h4>Excluded clinical studies for review question: Which people having neoadjuvant radiotherapy or chemoradiotherapy for rectal cancer do not need surgery?</h4><p id="ch6.appk.tab1"><a href="/books/NBK559938/table/ch6.appk.tab1/?report=objectonly" target="object" rid-ob="figobch6appktab1" class="figpopup">Table 5. Excluded studies and reasons for their exclusion</a></p></div></div><div id="ch6.appl"><h3>Appendix L. Research recommendations</h3><div id="ch6.appl.s1"><h4>Research recommendations for review question: Which people having neoadjuvant radiotherapy or chemoradiotherapy for rectal cancer do not need surgery?</h4><p>No research recommendations were made for this review question.</p></div></div></div></div><div class="fm-sec"><div><p>Final</p></div><div><p>Evidence reviews</p><p>Developed by the National Guideline Alliance part of the Royal College of Obstetricians and Gynaecologists</p></div><div><p><b>Disclaimer</b>: The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or service users. The recommendations in this guideline are not mandatory and the guideline does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or their carer or guardian.</p><p>Local commissioners and/or providers have a responsibility to enable the guideline to be applied when individual health professionals and their patients or service users wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with compliance with those duties.</p><p>NICE guidelines cover health and care in England. Decisions on how they apply in other UK countries are made by ministers in the <a href="http://wales.gov.uk/" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Welsh Government</a>, <a href="http://www.scotland.gov.uk/" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Scottish Government</a>, and <a href="http://www.northernireland.gov.uk/" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Northern Ireland Executive</a>. All NICE guidance is subject to regular review and may be updated or withdrawn.</p></div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © NICE 2020.</div><div class="small"><span class="label">Bookshelf ID: NBK559938</span><span class="label">PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/32730007" title="PubMed record of this title" ref="pagearea=meta&targetsite=entrez&targetcat=link&targettype=pubmed">32730007</a></span></div></div><div class="small-screen-prev"></div><div class="small-screen-next"></div></article><article data-type="table-wrap" id="figobch6tab1"><div id="ch6.tab1" class="table"><h3><span class="label">Table 1</span><span class="title">Summary of the protocol (PFO table)</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK559938/table/ch6.tab1/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ch6.tab1_lrgtbl__"><table class="no_bottom_margin"><tbody><tr><th id="hd_b_ch6.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Population</th><td headers="hd_b_ch6.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Adults with non-metastatic rectal cancer who have complete clinical response to neoadjuvant radiotherapy or chemoradiotherapy and are fit for, but who have not had, surgery.</td></tr><tr><th id="hd_b_ch6.tab1_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Factors</th><td headers="hd_b_ch6.tab1_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><ul id="ch6.l1"><li id="ch6.lt1" class="half_rhythm"><div>Patient characteristics
|
|
<ul id="ch6.l2" class="circle"><li id="ch6.lt2" class="half_rhythm"><div>Age (life expectancy)</div></li></ul></div></li><li id="ch6.lt3" class="half_rhythm"><div>Disease characteristics
|
|
<ul id="ch6.l3" class="circle"><li id="ch6.lt4" class="half_rhythm"><div>Radiological T stage</div></li><li id="ch6.lt5" class="half_rhythm"><div>Radiological N stage</div></li><li id="ch6.lt6" class="half_rhythm"><div>Radiological extra-mural vascular invasion</div></li><li id="ch6.lt7" class="half_rhythm"><div>Tumour’s distance from anal verge</div></li></ul></div></li><li id="ch6.lt8" class="half_rhythm"><div>Tumour pathology / biology (from pre-treatment biopsy)
|
|
<ul id="ch6.l4" class="circle"><li id="ch6.lt9" class="half_rhythm"><div>Differentiation</div></li><li id="ch6.lt10" class="half_rhythm"><div>Lymphovascular invasion (LVI)</div></li><li id="ch6.lt11" class="half_rhythm"><div><i>RAS</i> mutations</div></li><li id="ch6.lt12" class="half_rhythm"><div><i>BRAF</i> mutations</div></li><li id="ch6.lt13" class="half_rhythm"><div><i>MSI</i></div></li></ul></div></li><li id="ch6.lt14" class="half_rhythm"><div>Carcinoembryonic antigen (CEA) levels
|
|
<ul id="ch6.l5" class="circle"><li id="ch6.lt15" class="half_rhythm"><div>Pre-treatment</div></li><li id="ch6.lt16" class="half_rhythm"><div>Post-chemoradiotherapy</div></li><li id="ch6.lt17" class="half_rhythm"><div>Change from pre- to post-treatment</div></li></ul></div></li><li id="ch6.lt18" class="half_rhythm"><div>Tumour regression grade (TRG)</div></li></ul>
|
|
</td></tr><tr><th id="hd_b_ch6.tab1_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Outcomes</th><td headers="hd_b_ch6.tab1_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><b>Critical</b>
|
|
<ul id="ch6.l6"><li id="ch6.lt19" class="half_rhythm"><div>Locoregional progression or recurrence</div></li><li id="ch6.lt20" class="half_rhythm"><div>Overall survival</div></li><li id="ch6.lt21" class="half_rhythm"><div>Disease-free survival</div></li></ul>
|
|
<b>Important</b>
|
|
<ul id="ch6.l7"><li id="ch6.lt22" class="half_rhythm"><div>Organ preservation rate</div></li></ul></td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">BRAF: v-raf murine sarcoma b-viral oncogene homolog B1; CEA: carcinoembryonic antigen; LVI: lymphovascular invasion; MSI: microsatellite instability; RAS: rat sarcoma virus oncogene homolog; TRG: tumour regression grade.</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobch6appatab1"><div id="ch6.appa.tab1" class="table"><h3><span class="label">Table 2</span><span class="title">Review protocol for deferral of surgery in people having neoadjuvant therapy for rectal cancer</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK559938/table/ch6.appa.tab1/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ch6.appa.tab1_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_ch6.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Field (based on <a href="http://www.prisma-statement.org/Extensions/Protocols.aspx" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">PRISMA-P</a>)</th><th id="hd_h_ch6.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Content</th></tr></thead><tbody><tr><td headers="hd_h_ch6.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Review question</td><td headers="hd_h_ch6.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Which people having neoadjuvant radiotherapy or chemoradiotherapy for rectal cancer do not need surgery?</td></tr><tr><td headers="hd_h_ch6.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Type of review question</td><td headers="hd_h_ch6.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Prognostic/clinical prediction review</td></tr><tr><td headers="hd_h_ch6.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Objective of the review</td><td headers="hd_h_ch6.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">To determine the predictors for people having neoadjuvant chemotherapy or chemoradiotherapy for rectal cancer who do not need surgery.</td></tr><tr><td headers="hd_h_ch6.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Eligibility criteria – population/disease/condition/issue/domain</td><td headers="hd_h_ch6.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Adults with non-metastatic rectal cancer who have complete clinical response to neoadjuvant radiotherapy or chemoradiotherapy and are fit for, but who have not had, surgery.</p>
|
|
<p>Rectal cancer: defined as any tumour within 15 cm from anal verge excluding anal canal.</p>
|
|
</td></tr><tr><td headers="hd_h_ch6.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Eligibility criteria – intervention(s)/exposure(s)/prognostic factor(s)</td><td headers="hd_h_ch6.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><p>Included studies must have at least 5 of the following predictor variables in their models</p>
|
|
<p>Predictors:
|
|
<ul id="ch6.l8"><li id="ch6.lt23" class="half_rhythm"><div>Patient characteristics
|
|
<ul id="ch6.l9" class="circle"><li id="ch6.lt24" class="half_rhythm"><div>Age (life expectancy)</div></li></ul></div></li><li id="ch6.lt25" class="half_rhythm"><div>Disease characteristics
|
|
<ul id="ch6.l10" class="circle"><li id="ch6.lt26" class="half_rhythm"><div>Radiological T stage</div></li><li id="ch6.lt27" class="half_rhythm"><div>Radiological N stage</div></li><li id="ch6.lt28" class="half_rhythm"><div>Radiological extra-mural vascular invasion</div></li><li id="ch6.lt29" class="half_rhythm"><div>Tumour’s distance from anal verge</div></li></ul></div></li><li id="ch6.lt30" class="half_rhythm"><div>Tumour pathology / biology (from pre-treatment biopsy)
|
|
<ul id="ch6.l11" class="circle"><li id="ch6.lt31" class="half_rhythm"><div>Differentiation</div></li><li id="ch6.lt32" class="half_rhythm"><div>Lymphovascular invasion (LVI)</div></li><li id="ch6.lt33" class="half_rhythm"><div><i>RAS</i> mutations</div></li><li id="ch6.lt34" class="half_rhythm"><div><i>BRAF</i> mutations</div></li><li id="ch6.lt35" class="half_rhythm"><div><i>MSI</i></div></li></ul></div></li><li id="ch6.lt36" class="half_rhythm"><div>Carcinoembryonic antigen (CEA) levels
|
|
<ul id="ch6.l12" class="circle"><li id="ch6.lt37" class="half_rhythm"><div>Pre-treatment</div></li><li id="ch6.lt38" class="half_rhythm"><div>Post-chemoradiotherapy</div></li><li id="ch6.lt39" class="half_rhythm"><div>Change from pre- to post-treatment</div></li></ul></div></li><li id="ch6.lt40" class="half_rhythm"><div>Tumour regression grade (TRG)</div></li></ul></p></td></tr><tr><td headers="hd_h_ch6.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Confounding factors</td><td headers="hd_h_ch6.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Analysis should adjust for important confounding factors, such as:
|
|
<ul id="ch6.l13"><li id="ch6.lt41" class="half_rhythm"><div>Time interval between neoadjuvant therapy and response assessment</div></li><li id="ch6.lt42" class="half_rhythm"><div>Active surveillance protocol</div></li></ul></p>
|
|
</td></tr><tr><td headers="hd_h_ch6.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Outcomes and prioritisation</td><td headers="hd_h_ch6.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Critical:
|
|
<ul id="ch6.l14"><li id="ch6.lt43" class="half_rhythm"><div>Locoregional progression/recurrence (minimally important difference [MID]: local progression risk > 5% for decision to have immediate surgery (time dependent))</div></li><li id="ch6.lt44" class="half_rhythm"><div>Overall survival (MID: statistical significance)</div></li><li id="ch6.lt45" class="half_rhythm"><div>Disease-free survival (MID: statistical significance)</div></li></ul>
|
|
Important:
|
|
<ul id="ch6.l15"><li id="ch6.lt46" class="half_rhythm"><div>Organ preservation rate (MID: statistical significance)</div></li></ul></td></tr><tr><td headers="hd_h_ch6.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Eligibility criteria – study design</td><td headers="hd_h_ch6.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Include published full text papers:
|
|
<ul id="ch6.l16"><li id="ch6.lt47" class="half_rhythm"><div>Systematic reviews/meta-analyses of cohort studies</div></li><li id="ch6.lt48" class="half_rhythm"><div>RCTs (post-hoc analysis from trials with long follow-up periods)</div></li><li id="ch6.lt49" class="half_rhythm"><div>Prospective cohort studies</div></li><li id="ch6.lt50" class="half_rhythm"><div>Retrospective cohort studies</div></li></ul></td></tr><tr><td headers="hd_h_ch6.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Other inclusion exclusion criteria</td><td headers="hd_h_ch6.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><p>Inclusion:</p>
|
|
<p>English-language</p>
|
|
<p>All settings will be considered that consider medications and treatments available in the UK</p>
|
|
<p>Studies published post 2000</p>
|
|
<p>Studies published post 2000 will be considered for this review question, as the guideline committee considered that significant advances have occurred in rectal cancer management since this time period and outcomes for patients with rectal cancer prior to 2000 are not the same as post 2000.</p></td></tr><tr><td headers="hd_h_ch6.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Proposed sensitivity/sub-group analysis, or meta-regression</td><td headers="hd_h_ch6.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">In the case of high heterogeneity, the following factors will be considered:
|
|
<ul id="ch6.l17"><li id="ch6.lt51" class="half_rhythm"><div>Time interval between neoadjuvant therapy and response assessment</div></li><li id="ch6.lt52" class="half_rhythm"><div>Active surveillance protocol</div></li></ul></td></tr><tr><td headers="hd_h_ch6.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Selection process – duplicate screening/selection/analysis</td><td headers="hd_h_ch6.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Sifting, data extraction and appraisal of methodological quality will be performed by the systematic reviewer. Any disputes will be resolved in discussion with the senior systematic reviewer and the Topic Advisor. Quality control will be performed by the senior systematic reviewer.</p>
|
|
<p>Dual sifting will be undertaken for this question for a random 10% sample of the titles and abstracts identified by the search.</p>
|
|
</td></tr><tr><td headers="hd_h_ch6.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Data management (software)</td><td headers="hd_h_ch6.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NGA STAR software will be used for study sifting, data extraction, recording quality assessment using checklists and generating bibliographies/citations.</td></tr><tr><td headers="hd_h_ch6.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Information sources – databases and dates</td><td headers="hd_h_ch6.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><p>Potential sources to be searched (to be confirmed by the Information Scientist): Medline, Medline In-Process, CCTR, CDSR, DARE, HTA, Embase</p>
|
|
<p>Limits (e.g. date, study design):</p>
|
|
<p>Apply standard animal/non-English language exclusion</p>
|
|
<p>Dates: from 2000</p></td></tr><tr><td headers="hd_h_ch6.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Identify if an update</td><td headers="hd_h_ch6.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Not an update</td></tr><tr><td headers="hd_h_ch6.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Author contacts</td><td headers="hd_h_ch6.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="https://www.nice.org.uk/guidance/indevelopment/gid-ng10060" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">https://www<wbr style="display:inline-block"></wbr>​.nice.org<wbr style="display:inline-block"></wbr>​.uk/guidance/indevelopment/gid-ng10060</a> Developer: NGA</td></tr><tr><td headers="hd_h_ch6.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Highlight if amendment to previous protocol</td><td headers="hd_h_ch6.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">For details please see section 4.5 of <a href="https://www.nice.org.uk/article/pmg20/chapter/4-Developing-review-questions-and-planning-the-evidence-review#planning-the-evidence-review" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Developing NICE guidelines: the manual</a></td></tr><tr><td headers="hd_h_ch6.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Search strategy – for one database</td><td headers="hd_h_ch6.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">For details please see <a href="#ch6.appb">appendix B</a>.</td></tr><tr><td headers="hd_h_ch6.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Data collection process – forms/duplicate</td><td headers="hd_h_ch6.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">A standardised evidence table format was used, see <a href="#ch6.appd">appendix D</a> (clinical evidence tables) and <a href="#ch6.apph">H</a> (economic evidence tables).</td></tr><tr><td headers="hd_h_ch6.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Data items – define all variables to be collected</td><td headers="hd_h_ch6.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">For details please see evidence tables in <a href="#ch6.appd">appendix D</a> (clinical evidence tables) or <a href="#ch6.apph">H</a> (economic evidence tables).</td></tr><tr><td headers="hd_h_ch6.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Methods for assessing bias at outcome/study level</td><td headers="hd_h_ch6.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><p>Standard study checklists were used to critically appraise individual studies. For details please see section 6.2 of <a href="https://www.nice.org.uk/article/pmg20/chapter/6-Reviewing-research-evidence#assessing-the-quality-of-the-evidence" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Developing NICE guidelines: the manual</a></p>
|
|
<p>Appraisal of methodological quality:</p>
|
|
<p>The methodological quality of each study will be assessed using an appropriate checklist:
|
|
<ul id="ch6.l18"><li id="ch6.lt53" class="half_rhythm"><div>ROBIS for systematic reviews</div></li><li id="ch6.lt54" class="half_rhythm"><div>Quality in prognostic studies (QUIPS) tool</div></li><li id="ch6.lt55" class="half_rhythm"><div>ROBINS-I for non-randomised studies</div></li></ul></p></td></tr><tr><td headers="hd_h_ch6.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Criteria for quantitative synthesis (where suitable)</td><td headers="hd_h_ch6.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Meta-analyses will be not be conducted for this prognostic review.</td></tr><tr><td headers="hd_h_ch6.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Methods for analysis – combining studies and exploring (in)consistency</td><td headers="hd_h_ch6.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">The adjusted odds ratios and 95% confidence intervals will be plotted in RevMan, however pooled results will not be calculated. The forest plots will be used to visually see the studies alongside each other and to explore similarities and differences between studies.</td></tr><tr><td headers="hd_h_ch6.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Meta-bias assessment – publication bias, selective reporting bias</td><td headers="hd_h_ch6.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">For details please see section 6.2 of <a href="https://www.nice.org.uk/article/pmg20/chapter/6-Reviewing-research-evidence#assessing-the-quality-of-the-evidence" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Developing NICE guidelines: the manual</a>.</td></tr><tr><td headers="hd_h_ch6.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Assessment of confidence in cumulative evidence</td><td headers="hd_h_ch6.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">For details please see sections 6.4 and 9.1 of <a href="https://www.nice.org.uk/article/pmg20/chapter/1-Introduction-and-overview" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Developing NICE guidelines: the manual</a></td></tr><tr><td headers="hd_h_ch6.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Rationale/context – Current management</td><td headers="hd_h_ch6.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">For details please see the introduction to the evidence review.</td></tr><tr><td headers="hd_h_ch6.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Describe contributions of authors and guarantor</td><td headers="hd_h_ch6.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><p>A multidisciplinary committee developed the guideline. The committee was convened by The National Guideline Alliance and chaired by Peter Hoskin in line with section 3 of <a href="https://www.nice.org.uk/article/pmg20/chapter/1%20Introduction%20and%20overview" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Developing NICE guidelines: the manual</a>.</p>
|
|
<p>Staff from The National Guideline Alliance undertook systematic literature searches, appraised the evidence, conducted meta-analysis and cost-effectiveness analysis where appropriate, and drafted the guideline in collaboration with the committee. For details please see Supplement 1.</p></td></tr><tr><td headers="hd_h_ch6.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Sources of funding/support</td><td headers="hd_h_ch6.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">The National Guideline Alliance is funded by NICE and hosted by the Royal College of Obstetricians and Gynaecologists</td></tr><tr><td headers="hd_h_ch6.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Name of sponsor</td><td headers="hd_h_ch6.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">The National Guideline Alliance is funded by NICE and hosted by the Royal College of Obstetricians and Gynaecologists</td></tr><tr><td headers="hd_h_ch6.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Roles of sponsor</td><td headers="hd_h_ch6.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NICE funds The National Guideline Alliance to develop guidelines for those working in the NHS, public health, and social care in England</td></tr><tr><td headers="hd_h_ch6.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PROSPERO registration number</td><td headers="hd_h_ch6.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Not registered</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">BRAF: v-raf murine sarcoma b-viral oncogene homolog B1; CCTR: Cochrane Controlled Trials Register; CEA: carcinoembryonic antigen; CSDR: Cochrane Database of Systematic Reviews; DARE: Database of Abstracts of Reviews of Effects; HTA: Health Technology Assessment; LVI: lymphovascular invasion; MID: minimal important difference; MSI: microsatellite instability; NGA: National Guidelines Alliance; NHS: National Health Service; NICE: National Institute for Health and Care Excellence; PRISMA-P: Preferred Reporting Items for Systematic Reviews and Meta-Analysis for Protocols; PROSPERO: International prospective register of systematic reviews; QUIPS: Quality in prognostic studies; RAS: rat sarcoma virus oncogene homolog; RCT: randomised controlled trial; ROBINS-I: risk of bias in non-randomised studies of interventions; ROBIS: risk of bias in systematic reviews; TNM: cancer classification system, standing for tumour, nodal and metastasis stages; QUIPS: quality in prognosis studies</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobch6appbtab1"><div id="ch6.appb.tab1" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK559938/table/ch6.appb.tab1/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ch6.appb.tab1_lrgtbl__"><table><thead><tr><th id="hd_h_ch6.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">#</th><th id="hd_h_ch6.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Search</th></tr></thead><tbody><tr><td headers="hd_h_ch6.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_ch6.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Rectal Neoplasms/ use prmz</td></tr><tr><td headers="hd_h_ch6.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2</td><td headers="hd_h_ch6.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">*rectum cancer/ or *rectum tumor/</td></tr><tr><td headers="hd_h_ch6.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3</td><td headers="hd_h_ch6.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2 use oemezd</td></tr><tr><td headers="hd_h_ch6.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">4</td><td headers="hd_h_ch6.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Adenocarcinoma/</td></tr><tr><td headers="hd_h_ch6.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">5</td><td headers="hd_h_ch6.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(T1 or T2 or N0 or M0).ti,ab.</td></tr><tr><td headers="hd_h_ch6.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">6</td><td headers="hd_h_ch6.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1 or 3</td></tr><tr><td headers="hd_h_ch6.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">7</td><td headers="hd_h_ch6.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">4 or 5</td></tr><tr><td headers="hd_h_ch6.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">8</td><td headers="hd_h_ch6.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">6 and 7</td></tr><tr><td headers="hd_h_ch6.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">9</td><td headers="hd_h_ch6.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((rectal or rectum) adj3 (cancer* or neoplas* or malignan* or tumo?r* or carcinom* or adeno*)).ti,ab.</td></tr><tr><td headers="hd_h_ch6.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">10</td><td headers="hd_h_ch6.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">early rect* cancer.ti,ab.</td></tr><tr><td headers="hd_h_ch6.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">11</td><td headers="hd_h_ch6.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">6 or 8 or 9 or 10</td></tr><tr><td headers="hd_h_ch6.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">12</td><td headers="hd_h_ch6.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp radiotherapy/ or exp radiation oncology/ or exp external beam radiotherapy/ or exp Brachytherapy/ or exp preoperative care/ or exp neoadjuvant therapy/ or exp multimodality cancer therapy/ or exp chemotherapy/ or exp antineoplastic agent/ or exp drug therapy/ or exp chemoradiotherapy/ or exp fluorouracil/ or exp folinic acid/ or exp capecitabine/ or exp oxaliplatin/ or exp bevacizumab/ or exp methotrexate/ or exp radiation dose fractionation/ or exp tumor recurrence/ or exp radiotherapy dosage/</td></tr><tr><td headers="hd_h_ch6.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">13</td><td headers="hd_h_ch6.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">12 use oemezd</td></tr><tr><td headers="hd_h_ch6.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">14</td><td headers="hd_h_ch6.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Radiotherapy/ or exp Radiation Oncology/ or exp Radiotherapy, Computer-Assisted/ or exp Brachytherapy/ or exp Preoperative Care/ or exp Neoadjuvant Therapy/ or exp Combined Modality Therapy/ or exp Chemoradiotherapy/ or exp Antineoplastic Combined Chemotherapy Protocols/ or exp Drug Therapy/ or exp Antineoplastic Agents/ or exp Fluorouracil/ or exp Leucovorin/ or exp Capecitabine/ or exp Bevacizumab/ or exp Methotrexate/ or exp Dose Fractionation/ or exp radiotherapy dosage/</td></tr><tr><td headers="hd_h_ch6.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">15</td><td headers="hd_h_ch6.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">14 use prmz</td></tr><tr><td headers="hd_h_ch6.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">16</td><td headers="hd_h_ch6.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((radiotherap* or chemoradio* or radiation or brachytherapy* or chemotherapy*) adj (pre?op* or preop* or periop* or neoadjuvant)).ti,ab.</td></tr><tr><td headers="hd_h_ch6.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">17</td><td headers="hd_h_ch6.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(5-fluorouracil or 5-FU or leucovorin or folinic acid or capecitabine or oxaliplatin or bevacizumab or methotrexate or dose* or fraction* or recurren*).ti,ab.</td></tr><tr><td headers="hd_h_ch6.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">18</td><td headers="hd_h_ch6.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">13 or 15 or 16 or 17</td></tr><tr><td headers="hd_h_ch6.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">19</td><td headers="hd_h_ch6.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Organ Preservation/ or Organ Sparing Treatments/ or exp Treatment Outcome/ or exp Disease-Free Survival/ or exp Neoplasm Recurrence, Local/ or exp Neoplasm, Residual/ or exp Lymph Nodes/ or exp Risk Factors/ or exp Prognosis/ or exp Observation/ or exp Watchful Waiting/ or exp Time Factors/ or exp Comorbidity/ or exp Age Factors/ or exp Health Status/ or exp Health Status Indicators/ or exp Morbidity/ or exp Physical Fitness/</td></tr><tr><td headers="hd_h_ch6.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">20</td><td headers="hd_h_ch6.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">19 use prmz</td></tr><tr><td headers="hd_h_ch6.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">21</td><td headers="hd_h_ch6.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp organ preservation/ or exp conservative treatment/ or exp treatment outcome/ or exp disease free survival/ or exp tumor recurrence/ or exp minimal residual disease/ or lymph node/ or exp lymph node/ or exp risk factor/ or exp prognosis/ or exp observation/ or exp watchful waiting/ or exp time factor/ or exp adjuvant therapy/ or exp cancer control/ or exp comorbidity/ or exp health status indicator/ or exp morbidity/ or age/ or exp performance/ or fitness/ or (exp patient/ and exp health status/)</td></tr><tr><td headers="hd_h_ch6.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">22</td><td headers="hd_h_ch6.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">21 use oemezd</td></tr><tr><td headers="hd_h_ch6.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">23</td><td headers="hd_h_ch6.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(prognos* or preservation or preserve* or sparing or complete response* or predict* or watch* or wait* or observ* or risk* or regrowth or recurren* or adjuvant or downstag* or downsize* or local control or residual or morbid* or poor perform* or delay* or unfit or fit or (lymph node adj (count or status)) or histolog* or outcome or ((avoid* or suit*) adj3 surger*)).ti,ab.</td></tr><tr><td headers="hd_h_ch6.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">24</td><td headers="hd_h_ch6.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">20 or 22 or 23</td></tr><tr><td headers="hd_h_ch6.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">25</td><td headers="hd_h_ch6.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">11 and 18 and 24</td></tr><tr><td headers="hd_h_ch6.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">26</td><td headers="hd_h_ch6.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">limit 25 to english language</td></tr><tr><td headers="hd_h_ch6.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">27</td><td headers="hd_h_ch6.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">limit 26 to yr=“2000 -Current”</td></tr><tr><td headers="hd_h_ch6.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">28</td><td headers="hd_h_ch6.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(conference abstract or letter).pt. or letter/ or editorial.pt. or note.pt. or case report/ or case study/ use oemezd</td></tr><tr><td headers="hd_h_ch6.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">29</td><td headers="hd_h_ch6.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Letter/ or editorial/ or news/ or historical article/ or anecdotes as topic/ or comment/ or case report/ use prmz</td></tr><tr><td headers="hd_h_ch6.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">30</td><td headers="hd_h_ch6.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(letter or comment* or abstracts).ti.</td></tr><tr><td headers="hd_h_ch6.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">31</td><td headers="hd_h_ch6.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">or/28–30</td></tr><tr><td headers="hd_h_ch6.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">32</td><td headers="hd_h_ch6.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomized controlled trial/ use prmz</td></tr><tr><td headers="hd_h_ch6.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">33</td><td headers="hd_h_ch6.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomized controlled trial/ use oemezd</td></tr><tr><td headers="hd_h_ch6.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">34</td><td headers="hd_h_ch6.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">random*.ti,ab.</td></tr><tr><td headers="hd_h_ch6.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">35</td><td headers="hd_h_ch6.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">or/32–34</td></tr><tr><td headers="hd_h_ch6.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">36</td><td headers="hd_h_ch6.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">31 not 35</td></tr><tr><td headers="hd_h_ch6.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">37</td><td headers="hd_h_ch6.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(animals/ not humans/) or exp animals, laboratory/ or exp animal experimentation/ or exp models, animal/ or exp rodentia/ use prmz</td></tr><tr><td headers="hd_h_ch6.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">38</td><td headers="hd_h_ch6.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(animal/ not human/) or nonhuman/ or exp animal experiment/ or exp experimental animal/ or animal model/ or exp rodent/ use oemezd</td></tr><tr><td headers="hd_h_ch6.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">39</td><td headers="hd_h_ch6.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(rat or rats or mouse or mice).ti.</td></tr><tr><td headers="hd_h_ch6.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">40</td><td headers="hd_h_ch6.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">36 or 37 or 38 or 39</td></tr><tr><td headers="hd_h_ch6.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">41</td><td headers="hd_h_ch6.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">27 not 40</td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobch6appbtab2"><div id="ch6.appb.tab2" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK559938/table/ch6.appb.tab2/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ch6.appb.tab2_lrgtbl__"><table><thead><tr><th id="hd_h_ch6.appb.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">#</th><th id="hd_h_ch6.appb.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Search</th></tr></thead><tbody><tr><td headers="hd_h_ch6.appb.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_ch6.appb.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MeSH descriptor: [Rectal Neoplasms] explode all trees</td></tr><tr><td headers="hd_h_ch6.appb.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2</td><td headers="hd_h_ch6.appb.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MeSH descriptor: [Adenocarcinoma] explode all trees</td></tr><tr><td headers="hd_h_ch6.appb.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3</td><td headers="hd_h_ch6.appb.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">T1 or T2 or N0 or M0</td></tr><tr><td headers="hd_h_ch6.appb.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">4</td><td headers="hd_h_ch6.appb.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#2 or #3</td></tr><tr><td headers="hd_h_ch6.appb.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">5</td><td headers="hd_h_ch6.appb.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#1 and #4</td></tr><tr><td headers="hd_h_ch6.appb.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">6</td><td headers="hd_h_ch6.appb.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(rectal or rectum) near (cancer* or neoplas* or malignan* or tumo?r* or carcinom* or adeno*)</td></tr><tr><td headers="hd_h_ch6.appb.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">7</td><td headers="hd_h_ch6.appb.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">early rect* cancer</td></tr><tr><td headers="hd_h_ch6.appb.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">8</td><td headers="hd_h_ch6.appb.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#1 or #5 or #6 or #7</td></tr><tr><td headers="hd_h_ch6.appb.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">9</td><td headers="hd_h_ch6.appb.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MeSH descriptor: [Radiotherapy] explode all trees</td></tr><tr><td headers="hd_h_ch6.appb.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">10</td><td headers="hd_h_ch6.appb.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MeSH descriptor: [Radiation Oncology] explode all trees</td></tr><tr><td headers="hd_h_ch6.appb.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">11</td><td headers="hd_h_ch6.appb.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MeSH descriptor: [Radiotherapy, Computer-Assisted] explode all trees</td></tr><tr><td headers="hd_h_ch6.appb.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">12</td><td headers="hd_h_ch6.appb.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MeSH descriptor: [Brachytherapy] explode all trees</td></tr><tr><td headers="hd_h_ch6.appb.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">13</td><td headers="hd_h_ch6.appb.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MeSH descriptor: [Preoperative Care] explode all trees</td></tr><tr><td headers="hd_h_ch6.appb.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">14</td><td headers="hd_h_ch6.appb.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MeSH descriptor: [Neoadjuvant Therapy] explode all trees</td></tr><tr><td headers="hd_h_ch6.appb.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">15</td><td headers="hd_h_ch6.appb.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MeSH descriptor: [Combined Modality Therapy] explode all trees</td></tr><tr><td headers="hd_h_ch6.appb.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">16</td><td headers="hd_h_ch6.appb.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MeSH descriptor: [Chemoradiotherapy] explode all trees</td></tr><tr><td headers="hd_h_ch6.appb.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">17</td><td headers="hd_h_ch6.appb.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MeSH descriptor: [Antineoplastic Combined Chemotherapy Protocols] explode all trees</td></tr><tr><td headers="hd_h_ch6.appb.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">18</td><td headers="hd_h_ch6.appb.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MeSH descriptor: [Drug Therapy] explode all trees</td></tr><tr><td headers="hd_h_ch6.appb.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">19</td><td headers="hd_h_ch6.appb.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MeSH descriptor: [Antineoplastic Agents] explode all trees</td></tr><tr><td headers="hd_h_ch6.appb.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">20</td><td headers="hd_h_ch6.appb.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MeSH descriptor: [Fluorouracil] explode all trees</td></tr><tr><td headers="hd_h_ch6.appb.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">21</td><td headers="hd_h_ch6.appb.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MeSH descriptor: [Capecitabine] explode all trees</td></tr><tr><td headers="hd_h_ch6.appb.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">22</td><td headers="hd_h_ch6.appb.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MeSH descriptor: [Bevacizumab] explode all trees</td></tr><tr><td headers="hd_h_ch6.appb.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">23</td><td headers="hd_h_ch6.appb.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MeSH descriptor: [Methotrexate] explode all trees</td></tr><tr><td headers="hd_h_ch6.appb.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">24</td><td headers="hd_h_ch6.appb.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MeSH descriptor: [Dose Fractionation] explode all trees</td></tr><tr><td headers="hd_h_ch6.appb.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">25</td><td headers="hd_h_ch6.appb.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(radiotherap* or chemoradio* or radiation or brachytherapy* or chemotherapy*) near (pre?op* or preop* or periop* or neoadjuvant)</td></tr><tr><td headers="hd_h_ch6.appb.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">26</td><td headers="hd_h_ch6.appb.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">5-fluorouracil or 5-FU or leucovorin or folinic acid or capecitabine or oxaliplatin or bevacizumab or methotrexate or dose* or fraction* or recurren*</td></tr><tr><td headers="hd_h_ch6.appb.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">27</td><td headers="hd_h_ch6.appb.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25 or #26</td></tr><tr><td headers="hd_h_ch6.appb.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">28</td><td headers="hd_h_ch6.appb.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MeSH descriptor: [Organ Preservation] explode all trees</td></tr><tr><td headers="hd_h_ch6.appb.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">29</td><td headers="hd_h_ch6.appb.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MeSH descriptor: [Organ Sparing Treatments] explode all trees</td></tr><tr><td headers="hd_h_ch6.appb.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">30</td><td headers="hd_h_ch6.appb.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MeSH descriptor: [Treatment Outcome] explode all trees</td></tr><tr><td headers="hd_h_ch6.appb.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">31</td><td headers="hd_h_ch6.appb.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MeSH descriptor: [Disease-Free Survival] explode all trees</td></tr><tr><td headers="hd_h_ch6.appb.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">32</td><td headers="hd_h_ch6.appb.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MeSH descriptor: [Neoplasm Recurrence, Local] explode all trees</td></tr><tr><td headers="hd_h_ch6.appb.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">33</td><td headers="hd_h_ch6.appb.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MeSH descriptor: [Neoplasm, Residual] explode all trees</td></tr><tr><td headers="hd_h_ch6.appb.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">34</td><td headers="hd_h_ch6.appb.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MeSH descriptor: [Lymph Nodes] explode all trees</td></tr><tr><td headers="hd_h_ch6.appb.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">35</td><td headers="hd_h_ch6.appb.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MeSH descriptor: [Risk Factors] explode all trees</td></tr><tr><td headers="hd_h_ch6.appb.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">36</td><td headers="hd_h_ch6.appb.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MeSH descriptor: [Prognosis] explode all trees</td></tr><tr><td headers="hd_h_ch6.appb.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">37</td><td headers="hd_h_ch6.appb.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MeSH descriptor: [Observation] explode all trees</td></tr><tr><td headers="hd_h_ch6.appb.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">38</td><td headers="hd_h_ch6.appb.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MeSH descriptor: [Watchful Waiting] explode all trees</td></tr><tr><td headers="hd_h_ch6.appb.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">39</td><td headers="hd_h_ch6.appb.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MeSH descriptor: [Time Factors] explode all trees</td></tr><tr><td headers="hd_h_ch6.appb.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">40</td><td headers="hd_h_ch6.appb.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">prognos* or preservation or preserve* or sparing or complete response* or predict* or watch* or wait* or observ* or risk* or regrowth or recurren* or adjuvant or downstag* or downsize* or local control or residual or histolog* or outcome</td></tr><tr><td headers="hd_h_ch6.appb.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">41</td><td headers="hd_h_ch6.appb.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">lymph node near (count or status)</td></tr><tr><td headers="hd_h_ch6.appb.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">42</td><td headers="hd_h_ch6.appb.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(avoid* or suit*) near surger*</td></tr><tr><td headers="hd_h_ch6.appb.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">43</td><td headers="hd_h_ch6.appb.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#28 or #29 or #30 or #31 or #32 or #33 or #34 or #35 or #36 or #37 or #38 or #39 or #40 or #41 or #42</td></tr><tr><td headers="hd_h_ch6.appb.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">44</td><td headers="hd_h_ch6.appb.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#8 and #27 and #43 Publication Year from 2000 to 2018</td></tr></tbody></table></div></div></article><article data-type="fig" id="figobch6appcfig1"><div id="ch6.appc.fig1" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%201.%20Study%20selection%20flow%20chart.&p=BOOKS&id=559938_ch6appcf1.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK559938/bin/ch6appcf1.jpg" alt="Figure 1. Study selection flow chart." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 1</span><span class="title">Study selection flow chart</span></h3></div></article><article data-type="table-wrap" id="figobch6appktab1"><div id="ch6.appk.tab1" class="table"><h3><span class="label">Table 5</span><span class="title">Excluded studies and reasons for their exclusion</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK559938/table/ch6.appk.tab1/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ch6.appk.tab1_lrgtbl__"><table><thead><tr><th id="hd_h_ch6.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Study</th><th id="hd_h_ch6.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reason for exclusion</th></tr></thead><tbody><tr><td headers="hd_h_ch6.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Abrams, M. J., Koffer, P. P., Leonard, K. L., The emerging non-operative management of non-metastatic rectal cancer: A population analysis, Anticancer Research, 36, 1699–1702, 2016 [<a href="https://pubmed.ncbi.nlm.nih.gov/27069148" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 27069148</span></a>]
|
|
</td><td headers="hd_h_ch6.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Patients not selected for complete clinical response</td></tr><tr><td headers="hd_h_ch6.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Alongi, F., Mazzola, R., Watch-and-wait versus surgical resection for patients with rectal cancer, The Lancet Oncology, 17, e133–e134, 2016 [<a href="https://pubmed.ncbi.nlm.nih.gov/27300671" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 27300671</span></a>]
|
|
</td><td headers="hd_h_ch6.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Letter in response to Renehan (2015)</td></tr><tr><td headers="hd_h_ch6.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Appelt, A. L., Ploen, J., Harling, H., Jensen, F. S., Jensen, L. H., Jorgensen, J. C. R., Lindebjerg, J., Rafaelsen, S. R., Jakobsen, A., High-dose chemoradiotherapy and watchful waiting for distal rectal cancer: A prospective observational study, The Lancet Oncology, 16, 919–927, 2015 [<a href="https://pubmed.ncbi.nlm.nih.gov/26156652" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 26156652</span></a>]
|
|
</td><td headers="hd_h_ch6.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No analysis of prognostic factors</td></tr><tr><td headers="hd_h_ch6.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Araujo, R. O. C., Valadao, M., Borges, D., Linhares, E., De Jesus, J. P., Ferreira, C. G., Victorino, A. P., Vieira, F. M., Albagli, R., Nonoperative management of rectal cancer after chemoradiation opposed to resection after complete clinical response. A comparative study, European Journal of Surgical Oncology, 41, 1456–1463, 2015 [<a href="https://pubmed.ncbi.nlm.nih.gov/26362228" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 26362228</span></a>]
|
|
</td><td headers="hd_h_ch6.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No multivariate prognostic analysis. Univariate data for: distance from anal verge.</td></tr><tr><td headers="hd_h_ch6.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Bannura, G., Outcome and salvage surgery following “watch and wait” for rectal cancer after neoadjuvant therapy: A systematic review, Revista Chilena de Cirugia, 352, 2017
|
|
</td><td headers="hd_h_ch6.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Non English language</td></tr><tr><td headers="hd_h_ch6.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Beets, G. L., Critical appraisal of the ‘wait and see’ approach in rectal cancer for clinical complete responders after chemoradiation, British Journal of Surgery, 99, 910, 2012 [<a href="https://pubmed.ncbi.nlm.nih.gov/22648639" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22648639</span></a>]
|
|
</td><td headers="hd_h_ch6.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Commentary on systematic review (Glynne-Jones. 2012)</td></tr><tr><td headers="hd_h_ch6.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Beets, G. L., What are We Going to Do with Complete Responses After Chemoradiation of Rectal Cancer?, Annals of Surgical Oncology, 23, 1801–1802, 2016 [<a href="https://pubmed.ncbi.nlm.nih.gov/26957500" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 26957500</span></a>]
|
|
</td><td headers="hd_h_ch6.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Expert review</td></tr><tr><td headers="hd_h_ch6.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Beets, G. L., Figueiredo, N. L., Habr-Gama, A., Van De Velde, C. J. H., A new paradigm for rectal cancer: Organ preservation Introducing the International Watch & Wait Database (IWWD), European Journal of Surgical Oncology, 41, 1562–1564, 2015 [<a href="https://pubmed.ncbi.nlm.nih.gov/26493223" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 26493223</span></a>]
|
|
</td><td headers="hd_h_ch6.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Describes watch-and-watch international database.</td></tr><tr><td headers="hd_h_ch6.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Benezery, K., Chamorey, E., Francois, E., Doyen, J., Gourgou-Bourgade, S., Gerard, J. P., Clinical complete response after neoadjuvant chemoradiotherapy (nCRT) of rectal cancer: A key end point to increase conservative treatment - Findings from the ACCORD12 randomized trial, European Journal of Cancer, 49, S501–S502, 2013
|
|
</td><td headers="hd_h_ch6.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Conference abstract</td></tr><tr><td headers="hd_h_ch6.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Bhangu, A., Kiran, R. P., Audisio, R., Tekkis, P., Survival outcome of operated and non-operated elderly patients with rectal cancer: A Surveillance, Epidemiology, and End Results analysis, European Journal of Surgical Oncology, 40, 1510–1516, 2014 [<a href="https://pubmed.ncbi.nlm.nih.gov/24704032" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 24704032</span></a>]
|
|
</td><td headers="hd_h_ch6.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Complete clinical response not an inclusion criteria</td></tr><tr><td headers="hd_h_ch6.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Bhatti, A. B. H., Zaheer, S., Shafique, K., Prognostic role of acellular mucin pools in patients with rectal cancer after pathological complete response to preoperative chemoradiation: Systematic review and meta-analysis, Journal of the College of Physicians and Surgeons Pakistan, 27, 714–718, 2017 [<a href="https://pubmed.ncbi.nlm.nih.gov/29132485" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 29132485</span></a>]
|
|
</td><td headers="hd_h_ch6.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Patients had surgery</td></tr><tr><td headers="hd_h_ch6.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Brooker, R., McKay, M., Crabtree, A., Wong, H., Sripadam, R., Organ sparing radiotherapy in rectal cancer: Definitive chemoradiation is a safe and valid option, Annals of Oncology, 26, iv96, 2015
|
|
</td><td headers="hd_h_ch6.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Conference abstract</td></tr><tr><td headers="hd_h_ch6.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Caderillo-Ruiz, G., Diaz, C., Lopez-Basave, H. N., Herrera, M. T., Ruiz Garcia, E., Melchor, J., Trejo, G., Aguilar, J. L., Gomez, A. H., Meneses-Garcia, A., Clinical outcome in patients who did not accept complementary surgery after neoadjuvant chemoradiotherapy (QT-RT) in locally advanced rectal cancer (LARC), Journal of Clinical Oncology. Conference, 34, 2016
|
|
</td><td headers="hd_h_ch6.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Conference abstract</td></tr><tr><td headers="hd_h_ch6.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Cotti, G., Nahas, C., Marques, C., Imperiale, A., Ribeiro
|
|
Jr, U., Nahas, S., Cecconello, I., Hoff, P., Outcomes of nonsurgical treatment in patients with clinical complete response after neoadjuvant therapy for rectal cancer, Diseases of the Colon and Rectum, 59 (5), e262, 2016
|
|
</td><td headers="hd_h_ch6.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Conference abstract</td></tr><tr><td headers="hd_h_ch6.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Dattani, M., Heald, R. J., Goussous, G., Broadhurst, J., Sao Juliao, G. P., Habr-Gama, A., Perez, R. O., Moran, B. J., Oncological and Survival Outcomes in Watch and Wait Patients With a Clinical Complete Response After Neoadjuvant Chemoradiotherapy for Rectal Cancer: A Systematic Review and Pooled Analysis, Annals of Surgery, 268, 955–967, 2018 [<a href="https://pubmed.ncbi.nlm.nih.gov/29746338" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 29746338</span></a>]
|
|
</td><td headers="hd_h_ch6.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Does not report prognostic analysis</td></tr><tr><td headers="hd_h_ch6.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Dickson-Lowe, R. A., Hanek, P., Kalaskar, S., Taylor, J., Non-operative management of low rectal cancer with complete response to standard neoadjuvant chemoradiotherapy, Gut, 1), A554–A555, 2015
|
|
</td><td headers="hd_h_ch6.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Conference abstract</td></tr><tr><td headers="hd_h_ch6.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Dossa, F., Chesney, T. R., Acuna, S. A., Baxter, N. N., A watch-and-wait approach for locally advanced rectal cancer after a clinical complete response following neoadjuvant chemoradiation: a systematic review and meta-analysis, The Lancet Gastroenterology and Hepatology, 2, 501–513, 2017 [<a href="https://pubmed.ncbi.nlm.nih.gov/28479372" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 28479372</span></a>]
|
|
</td><td headers="hd_h_ch6.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Systematic review, does not report prognostic factor analysis.</td></tr><tr><td headers="hd_h_ch6.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Glynne-Jones, R., Hughes, R., Critical appraisal of the ‘wait and see’ approach in rectal cancer for clinical complete responders after chemoradiation, British Journal of Surgery, 99, 897–909, 2012 [<a href="https://pubmed.ncbi.nlm.nih.gov/22539154" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22539154</span></a>]
|
|
</td><td headers="hd_h_ch6.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Systematic review, does not report prognostic factor analysis.</td></tr><tr><td headers="hd_h_ch6.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Glynne-Jones, R., Wallace, M., Livingstone, J. I. L., Meyrick-Thomas, J., Complete clinical response after preoperative chemoradiation in rectal cancer: Is a “wait and see” policy justified?, Diseases of the Colon and Rectum, 51, 10–19, 2008 [<a href="https://pubmed.ncbi.nlm.nih.gov/18043968" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 18043968</span></a>]
|
|
</td><td headers="hd_h_ch6.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Earlier version of Glynne-Jones (2012) systematic review</td></tr><tr><td headers="hd_h_ch6.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Gossedge, G., Montazeri, A., Nandhra, A., Wong, H., Artioukh, D., Zeiderman, M., Chipang, A., Myint, A., Complete clinical response to chemoradiotherapy for rectal cancer. Is it safe to ‘watch and wait’?, Colorectal Disease, 2), 20, 2012
|
|
</td><td headers="hd_h_ch6.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Conference abstract</td></tr><tr><td headers="hd_h_ch6.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Habr-Gama, A., Gama-Rodrigues, J., Sao Juliao, G. P., Proscurshim, I., Sabbagh, C., Lynn, P. B., Perez, R. O., Local recurrence after complete clinical response and watch and wait in rectal cancer after neoadjuvant chemoradiation: Impact of salvage therapy on local disease control, International Journal of Radiation Oncology Biology Physics, 88, 822–828, 2014 [<a href="https://pubmed.ncbi.nlm.nih.gov/24495589" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 24495589</span></a>]
|
|
</td><td headers="hd_h_ch6.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No multivariate prognostic analysis. Univariate data for: T stage, N stage.</td></tr><tr><td headers="hd_h_ch6.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Habr-Gama, A., Perez, R. O., Nadalin, W., Sabbaga, J., Ribeiro, U., Jr., Silva e Sousa, A. H., Jr., Campos, F. G., Kiss, D. R., GamaRodrigues, J., Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results, Annals of Surgery, 240, 711–7; discussion 717–8, 2004 [<a href="/pmc/articles/PMC1356472/" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC1356472</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/15383798" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15383798</span></a>]
|
|
</td><td headers="hd_h_ch6.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No prognostic factor analysis</td></tr><tr><td headers="hd_h_ch6.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Habr-Gama, A., Perez, R. O., Proscurshim, I., Campos, F. G., Nadalin, W., Kiss, D., Gama-Rodrigues, J., Patterns of Failure and Survival for Nonoperative Treatment of Stage c0 Distal Rectal Cancer Following Neoadjuvant Chemoradiation Therapy, Journal of Gastrointestinal Surgery, 10, 1319–1329, 2006 [<a href="https://pubmed.ncbi.nlm.nih.gov/17175450" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 17175450</span></a>]
|
|
</td><td headers="hd_h_ch6.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No multivariate prognostic analysis. Univariate data for: T stage, N stage.</td></tr><tr><td headers="hd_h_ch6.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Habr-Gama, A., Sabbaga, J., Gama-Rodrigues, J., Sao Juliao, G. P., Proscurshim, I., Bailao Aguilar, P., Nadalin, W., Perez, R. O., Watch and wait approach following extended neoadjuvant chemoradiation for distal rectal cancer: are we getting closer to anal cancer management?, Diseases of the Colon & RectumDis Colon Rectum, 56, 1109–17, 2013 [<a href="https://pubmed.ncbi.nlm.nih.gov/24022527" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 24022527</span></a>]
|
|
</td><td headers="hd_h_ch6.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No multivariate prognostic analysis. Univariate data for: T stage, N stage.</td></tr><tr><td headers="hd_h_ch6.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Habr-Gama, A., Sao Juliao, G. P., Perez, R. O., Nonoperative management of rectal cancer: Identifying the ideal patients, Hematology/Oncology Clinics of North America, 29, 135–151, 2015 [<a href="https://pubmed.ncbi.nlm.nih.gov/25475576" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 25475576</span></a>]
|
|
</td><td headers="hd_h_ch6.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Expert review</td></tr><tr><td headers="hd_h_ch6.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Heijnen, L. A., Maas, M., Martens, M. H., Lambregts, D. M. J., Van Drie, E., Stassen, L. P. S., Breukink, S. O., Leijtens, J. W. A., Beets-Tan, R. G. H., Beets, G. L., Endoscopy-based follow-up of clinical complete responders after chemoradiation for rectal cancer during a non-operative ‘wait-and-see’ policy, European Journal of Cancer, 2), S485, 2013
|
|
</td><td headers="hd_h_ch6.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Conference abstract</td></tr><tr><td headers="hd_h_ch6.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Hupkens, B., Martens, M., Kusters, M., Boelens, P., Meershoek-Klein Kranenbarg, E., Van Gestel, M., Ribeiro, R., Peeters, K., Perez, R., Figueiredo, N., Habr-Gama, A., Van De Velde, C., Beets, G., International watch and wait database: An international database of organ-preservation in rectal cancer, Colorectal Disease, 2), 68, 2015
|
|
</td><td headers="hd_h_ch6.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Conference abstract</td></tr><tr><td headers="hd_h_ch6.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Iseas
|
|
IS, Carballido
|
|
M, Coraglio
|
|
M, et al., Moving forward and beyond the standard through a non-operative management in rectal cancer?
|
|
Our watch and wait approach experience in CoRecto., Proc Am Soc Clin Oncol, 33, 2015
|
|
</td><td headers="hd_h_ch6.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Conference abstract</td></tr><tr><td headers="hd_h_ch6.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Jafari, M. D., Weiser, M. R., Personalizing Therapy for Locally Advanced Rectal Cancer, Current Colorectal Cancer Reports, 13, 119–125, 2017
|
|
</td><td headers="hd_h_ch6.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Expert review</td></tr><tr><td headers="hd_h_ch6.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Kessler, H., Matzel, K., Merkel, S., Fietkau, R., Hohenberger, W., Results of a “watch and wait” strategy in complete remission of rectal carcinoma after chemoradiotherapy, Diseases of the Colon and Rectum, 56 (4), e205, 2013
|
|
</td><td headers="hd_h_ch6.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Conference abstract</td></tr><tr><td headers="hd_h_ch6.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Kim, H. J., Song, J. H., Ahn, H. S., Choi, B. H., Jeong, H., Choi, H. S., Lee, Y. H., Kang, K. M., Jeong, B. K., Wait and see approach for rectal cancer with a clinically complete response after neoadjuvant concurrent chemoradiotherapy, International Journal of Colorectal Disease, 32, 723–727, 2017 [<a href="https://pubmed.ncbi.nlm.nih.gov/27885479" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 27885479</span></a>]
|
|
</td><td headers="hd_h_ch6.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Systematic review, does not report prognostic factor analysis.</td></tr><tr><td headers="hd_h_ch6.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Kong, J. C., Guerra, G. R., Warrier, S. K., Ramsay, R. G., Heriot, A. G., Outcome and Salvage Surgery Following “Watch and Wait” for Rectal Cancer after Neoadjuvant Therapy: A Systematic Review, Diseases of the Colon and Rectum, 60, 335–345, 2017 [<a href="https://pubmed.ncbi.nlm.nih.gov/28177997" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 28177997</span></a>]
|
|
</td><td headers="hd_h_ch6.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Systematic review, does not report prognostic factor analysis.</td></tr><tr><td headers="hd_h_ch6.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Kusters, M., Slater, A., Betts, M., Hompes, R., Guy, R. J., Jones, O. M., George, B. D., Lindsey, I., Mortensen, N. J., James, D. R., Cunningham, C., The treatment of all MRI-defined low rectal cancers in a single expert centre over a 5-year period: is there room for improvement?, Colorectal Disease, 18, O397–O404, 2016 [<a href="https://pubmed.ncbi.nlm.nih.gov/27313145" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 27313145</span></a>]
|
|
</td><td headers="hd_h_ch6.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Outcomes not reported for watch</td></tr><tr><td headers="hd_h_ch6.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Lai, C. L., Lai, M. J., Wu, C. C., Jao, S. W., Hsiao, C. W., Rectal cancer with complete clinical response after neoadjuvant chemoradiotherapy, surgery, or “watch and wait”, International Journal of Colorectal Disease, 31, 413–419, 2016 [<a href="https://pubmed.ncbi.nlm.nih.gov/26607907" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 26607907</span></a>]
|
|
</td><td headers="hd_h_ch6.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Does not report prognostic analysis.</td></tr><tr><td headers="hd_h_ch6.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Lambregts, D. M., Maas, M., Van Der Sande, M., Hupkens, B., Martens, M., Bakers, F., Beets-Tan, R. G. H., Breukink, S. O., Beets, G. L., Improving the selection of complete responders for watchful waiting after chemoradiotherapy for rectal cancer: What can we learn from the ‘missed’ pathologic complete responders after surgery?, United European Gastroenterology Journal, 5 (5 Supplement 1), A324, 2017
|
|
</td><td headers="hd_h_ch6.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Abstract only.</td></tr><tr><td headers="hd_h_ch6.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Latif, M, Day, N, Montazeri, A, Wait & see policy following complete clinical response to chemoradiotherapy in rectal cancer, single centre experience, Annals of oncology. Conference: 16th world congress on gastrointestinal cancer, ESMO 2014. Spain. Conference start: 20140625. Conference end: 20140628, 25, ii102–ii103, 2014
|
|
</td><td headers="hd_h_ch6.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Conference abstract</td></tr><tr><td headers="hd_h_ch6.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Li, J., Li, L., Yang, L., Yuan, J., Lv, B., Yao, Y., Xing, S., Wait-and-see treatment strategies for rectal cancer patients with clinical complete response after neoadjuvant chemoradiotherapy: A systematic review and meta-analysis, Oncotarget, 7, 44857–44870, 2016 [<a href="/pmc/articles/PMC5190140/" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC5190140</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27070085" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 27070085</span></a>]
|
|
</td><td headers="hd_h_ch6.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Systematic review, No prognostic analysis reported.</td></tr><tr><td headers="hd_h_ch6.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Li, J., Liu, H., Yin, J., Liu, S., Hu, J., Du, F., Yuan, J., Lv, B., Fan, J., Leng, S., Zhang, X., Wait-and-see or radical surgery for rectal cancer patients with a clinical complete response after neoadjuvant chemoradiotherapy: A cohort study, Oncotarget, 6, 42354–42361, 2015 [<a href="/pmc/articles/PMC4747231/" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4747231</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26472284" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 26472284</span></a>]
|
|
</td><td headers="hd_h_ch6.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No prognostic analysis reported.</td></tr><tr><td headers="hd_h_ch6.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Maas, M, Beets-Tan, Rgh, Lambregts, Dmj, Lammering, G, Nelemans, Pj, Engelen, Sme, Dam, Rm, Jansen, Rlh, Sosef, M, Leijtens, Jwa, Hulsewe, Kwe, Buijsen, J, Beets, Gl, Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer, Journal of Clinical Oncology, 29, 4633–4640, 2011 [<a href="https://pubmed.ncbi.nlm.nih.gov/22067400" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22067400</span></a>]
|
|
</td><td headers="hd_h_ch6.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No multivariate prognostic analysis. Univariate data for: T stage, N stage, distance from anal verge.</td></tr><tr><td headers="hd_h_ch6.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Martens, M. H., Maas, M., Heijnen, L. A., Lambregts, D. M. J., Leijtens, J. W. A., Stassen, L. P. S., Breukink, S. O., Hoff, C., Belgers, E. J., Melenhorst, J., Jansen, R., Buijsen, J., Hoofwijk, T. G. M., Beets-Tan, R. G. H., Beets, G. L., Long-term outcome of an organ preservation program after neoadjuvant treatment for rectal cancer, Journal of the National Cancer InstituteJ Natl Cancer Inst, 108 (12) (no pagination), 2016 [<a href="https://pubmed.ncbi.nlm.nih.gov/27509881" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 27509881</span></a>]
|
|
</td><td headers="hd_h_ch6.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No multivariate prognostic analysis. Univariate data for: T stage, N stage.</td></tr><tr><td headers="hd_h_ch6.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Mendoza, A. G., Morales, R. D., Russo, L., The first Venezuelan experience in nonoperative management of rectal cancer with complete clinical response following neoadjuvant therapy, Revista Venezolana de Oncologia, 29, 65–75, 2017
|
|
</td><td headers="hd_h_ch6.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Not English language</td></tr><tr><td headers="hd_h_ch6.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Myint, As, Smith, F, Whitmarsh, K, Wong, H, Pritchard, M, Non surgical treatment of operable rectal cancer: reducing harm from the standard of care in elderly patients, European journal of surgical oncology. Conference: joint BASO-ACS annual scientific conference and NCRI cancer conference 2016. United kingdom. Conference start: 20161106. Conference end: 20161109, 42, S228–s229, 2016
|
|
</td><td headers="hd_h_ch6.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Conference abstract</td></tr><tr><td headers="hd_h_ch6.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Nahas, C. S., Nahas, S. C., Marques, C. F., Ribeiro
|
|
Jr, U., Bustamante-Lopez, L. A., Cecconello, I., Randomized controlled trial for complete clinical response in patients with locally advanced rectal cancer after neoadjuvant chemoradiotherapy: Observation versus surgical resection, European Journal of Surgical Oncology, 41, S148, 2015
|
|
</td><td headers="hd_h_ch6.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Conference abstract</td></tr><tr><td headers="hd_h_ch6.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Nahas, S., Nahas, C., Ribeiro
|
|
Jr, U., Sparapan Marques, C., Cotti, G. C., Imperiale, A., Ortega, C., Azambuja, R., Chen, A., Hoff, P., Cecconello, I., Observation versus surgical resection in patients with rectal cancer who achieved complete clinical response after neoadjuvant chemoradiotherapy: Preliminary results of a randomized trial (NCT02052921), Diseases of the Colon and Rectum, 58 (5), e103–e104, 2015
|
|
</td><td headers="hd_h_ch6.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Conference abstract</td></tr><tr><td headers="hd_h_ch6.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Nahas, Sc, Rizkallah, Nahas Cs, Sparapan, Marques Cf, Ribeiro, U, Cotti, Gc, Imperiale, Ar, Capareli, Fc, Chih, Chen At, Hoff, Pm, Cecconello, I, Pathologic Complete Response in Rectal Cancer: can We Detect It? Lessons Learned From a Proposed Randomized Trial of Watch-and-Wait Treatment of Rectal Cancer, Diseases of the Colon and Rectum, 59, 255–263, 2016 [<a href="https://pubmed.ncbi.nlm.nih.gov/26953983" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 26953983</span></a>]
|
|
</td><td headers="hd_h_ch6.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N=4, no recurrence events.</td></tr><tr><td headers="hd_h_ch6.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Narang, S., Alam, N., Smart, N., Daniels, I., Non-operative management of Rectal Cancer: Too much hype?, Colorectal Disease, 2), 15, 2015
|
|
</td><td headers="hd_h_ch6.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Conference abstract</td></tr><tr><td headers="hd_h_ch6.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Neuman, H. B., Elkin, E. B., Guillem, J. G., Paty, P. B., Weiser, M. R., Wong, W. D., Temple, L. K., Treatment for patients with rectal cancer and a clinical complete response to neoadjuvant therapy: A decision analysis, Diseases of the Colon and Rectum, 52, 863–871, 2009 [<a href="https://pubmed.ncbi.nlm.nih.gov/19502849" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19502849</span></a>]
|
|
</td><td headers="hd_h_ch6.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Decision model (not a primary study) - relapse rates during observation alone based on expert opinion.</td></tr><tr><td headers="hd_h_ch6.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Perez, R. O., Habr-Gama, A., Gama-Rodrigues, J., Proscurshim, I., Juliao, G. P. S., Lynn, P., Ono, C. R., Campos, F. G., Silva, E.
|
|
Sousa
|
|
Jr
|
|
A. H., Imperiale, A. R., Nahas, S. C., Buchpiguel, C. A., Accuracy of positron emission tomography/computed tomography and clinical assessment in the detection of complete rectal tumor regression after neoadjuvant chemoradiation: Long-term results of a prospective trial (National Clinical Trial 00254683), Cancer, 118, 3501–3511, 2012 [<a href="https://pubmed.ncbi.nlm.nih.gov/22086847" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22086847</span></a>]
|
|
</td><td headers="hd_h_ch6.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Combines surgically and non-surgically treated patients</td></tr><tr><td headers="hd_h_ch6.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Rao, C., Sun Myint, A., Athanasiou, T., Faiz, O., Martin, A. P., Collins, B., Smith, F. M., Avoiding Radical Surgery in Elderly Patients With Rectal Cancer Is Cost-Effective, Diseases of the Colon & RectumDis Colon Rectum, 60, 30–42, 2017 [<a href="https://pubmed.ncbi.nlm.nih.gov/27926555" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 27926555</span></a>]
|
|
</td><td headers="hd_h_ch6.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Cost effectiveness study</td></tr><tr><td headers="hd_h_ch6.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Renehan, A. G., Malcomson, L., Emsley, R., Watch-and-wait approach for rectal cancer: concepts of a subject-specific method, The Lancet Gastroenterology and Hepatology, 2, 627, 2017 [<a href="https://pubmed.ncbi.nlm.nih.gov/28786383" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 28786383</span></a>]
|
|
</td><td headers="hd_h_ch6.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Letter in response to Dossa (2017) metaanalysis.</td></tr><tr><td headers="hd_h_ch6.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Renehan, A. G., Malcomson, L., Emsley, R., Gollins, S., Maw, A., Myint, A. S., Rooney, P. S., Susnerwala, S., Blower, A., Saunders, M. P., Wilson, M. S., Scott, N., O’Dwyer, S. T., Watch-and-wait approach versus surgical resection after chemoradiotherapy for patients with rectal cancer (the OnCoRe project): A propensity-score matched cohort analysis, The Lancet Oncology, 17, 174–183, 2016 [<a href="https://pubmed.ncbi.nlm.nih.gov/26705854" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 26705854</span></a>]
|
|
</td><td headers="hd_h_ch6.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No multivariate prognostic analysis for the watch and wait group</td></tr><tr><td headers="hd_h_ch6.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Renehan, A. G., Malcomson, L., Emsley, R., Scott, N., O’Dwyer, S. T., Watch-and-wait versus surgical resection for patients with rectal cancer - Authors’ reply, The Lancet Oncology, 17, e134–e135, 2016 [<a href="https://pubmed.ncbi.nlm.nih.gov/27300672" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 27300672</span></a>]
|
|
</td><td headers="hd_h_ch6.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Authors reply to a letter in response to Rehenan (2015)</td></tr><tr><td headers="hd_h_ch6.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Sammour, T., Price, B. A., Krause, K. J., Chang, G. J., Nonoperative Management or ‘Watch and Wait’ for Rectal Cancer with Complete Clinical Response After Neoadjuvant Chemoradiotherapy: A Critical Appraisal, Annals of Surgical Oncology, 24, 1904–1915, 2017 [<a href="/pmc/articles/PMC6106774/" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC6106774</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28324284" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 28324284</span></a>]
|
|
</td><td headers="hd_h_ch6.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Systematic review, prognostic analysis not reported</td></tr><tr><td headers="hd_h_ch6.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Sanchez Loria, F., Iseas, S., O’Connor, J. M., Pairola, A., Chacon, M., Mendez, G., Coraglio, M., Mariani, J., Dieguez, A., Roca, E., Huertas, E., Non-surgical management of rectal cancer. Series of 68 cases, long follow up in two leading centres in Argentina, Digestive and Liver Disease, 48, 1372–1377, 2016 [<a href="https://pubmed.ncbi.nlm.nih.gov/27260329" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 27260329</span></a>]
|
|
</td><td headers="hd_h_ch6.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No multivariate prognostic analysis. Univariate data for: T stage, N stage, CEA.</td></tr><tr><td headers="hd_h_ch6.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Schumacher, A., Rao, A., Loh, B. D., Dudukgian, H., Aboulian, A., McLemore, E. C., Attaluri, V., Rectal cancer: Nonoperative watch and wait vs standard of care surgical total mesorectal excision after complete clinical response to chemoradiation, a prospective cohort study, Journal of the American College of Surgeons, 225 (4 Supplement 1), S45, 2017
|
|
</td><td headers="hd_h_ch6.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Conference abstract</td></tr><tr><td headers="hd_h_ch6.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Seshadri, R. A., Kondaveeti, S. S., Jayanand, S. B., John, A., Rajendranath, R., Arumugam, V., Ellusamy, H. R., Sagar, T. G., Complete clinical response to neoadjuvant chemoradiation in rectal cancers: Can surgery be avoided?, Hepato-Gastroenterology, 60, 410–414, 2013 [<a href="https://pubmed.ncbi.nlm.nih.gov/23635444" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 23635444</span></a>]
|
|
</td><td headers="hd_h_ch6.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Does not report analysis adjusted for confounders</td></tr><tr><td headers="hd_h_ch6.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Smith, F. M., Al-Amin, A., Wright, A., Berry, J., Nicoll, J. J., Sun Myint, A., Contact radiotherapy boost in association with ‘watch and wait’ for rectal cancer: initial experience and outcomes from a shared programme between a district general hospital network and a regional oncology centre, Colorectal Disease, 18, 861–870, 2016 [<a href="https://pubmed.ncbi.nlm.nih.gov/26876570" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 26876570</span></a>]
|
|
</td><td headers="hd_h_ch6.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Entry criteria were not complete clinical response (some chose nonoperative management for other reasons).</td></tr><tr><td headers="hd_h_ch6.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Smith, F. M., Rao, C., Perez, R. O., Bujko, K., Athanasiou, T., Habr-Gama, A., Faiz, O., Avoiding radical surgery improves early survival in elderly patients with rectal cancer, demonstrating complete clinical response after neoadjuvant therapy: Results of a decision-analytic model, Diseases of the Colon and Rectum, 58, 159–171, 2015 [<a href="https://pubmed.ncbi.nlm.nih.gov/25585073" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 25585073</span></a>]
|
|
</td><td headers="hd_h_ch6.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Decision model (not primary study) - relapse rates during observation alone based on expert opinion.</td></tr><tr><td headers="hd_h_ch6.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Smith, F., Rao, C., Perez, R., Bujko, K., Athanasiou, T., Habr-Gama, A., Faiz, O., Avoiding radical surgery improves survival in elderly patients with rectal cancer demonstrating complete clinical response following neoadjuvant therapy: Results of a decision analytical model, Colorectal Disease, 2), 63, 2014 [<a href="https://pubmed.ncbi.nlm.nih.gov/25585073" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 25585073</span></a>]
|
|
</td><td headers="hd_h_ch6.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Conference abstract</td></tr><tr><td headers="hd_h_ch6.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Smith, J. D., Ruby, J. A., Goodman, K. A., Saltz, L. B., Guillem, J. G., Weiser, M. R., Temple, L. K., Nash, G. M., Paty, P. B., Nonoperative management of rectal cancer with complete clinical response after neoadjuvant therapy, Annals of Surgery, 256, 965–972, 2012 [<a href="https://pubmed.ncbi.nlm.nih.gov/23154394" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 23154394</span></a>]
|
|
</td><td headers="hd_h_ch6.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No multivariate prognostic analysis. Univariate data for: T stage, N stage</td></tr><tr><td headers="hd_h_ch6.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Smith, J. J., Chow, O. S., Gollub, M. J., Nash, G. M., Temple, L. K., Weiser, M. R., Guillem, J. G., Paty, P. B., Avila, K., Garcia-Aguilar, J., Rectal Cancer, Consortium, Organ Preservation in Rectal Adenocarcinoma: a phase II randomized controlled trial evaluating 3-year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total mesorectal excision or nonoperative management, BMC Cancer, 15, 767, 2015 [<a href="/pmc/articles/PMC4619249/" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4619249</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26497495" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 26497495</span></a>]
|
|
</td><td headers="hd_h_ch6.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Protocol for a phase II study.</td></tr><tr><td headers="hd_h_ch6.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Smith
|
|
J, Strombom
|
|
P, Chow
|
|
O, et al. Assessment of a Watch-and-Wait Strategy for Rectal Cancer in Patients with a Complete Response after Neoadjuvant Therapy, JAMA Oncology., 2018 [<a href="/pmc/articles/PMC6459120/" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC6459120</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30629084" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 30629084</span></a>]
|
|
</td><td headers="hd_h_ch6.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No multivariable prognostic analysis</td></tr><tr><td headers="hd_h_ch6.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Smith, J., Ruby, J., Goodman, K., Saltz, L., Guillem, J., Weiser, M., Temple, L., Nash, G., Paty, P., Non-operative management of rectal cancer with complete clinical response following neoadjuvant therapy, Irish Journal of Medical Science, 6), S183, 2012
|
|
</td><td headers="hd_h_ch6.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Conference abstract</td></tr><tr><td headers="hd_h_ch6.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Souza, J., Guimaraes, R., Siqueira, M. B., Gil, R., Araujo, R., Valadao, M., Watch and wait versus surgery with pathological complete response: Single institution experience, Annals of Oncology, 28 (Supplement 5), v204, 2017
|
|
</td><td headers="hd_h_ch6.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Conference abstract</td></tr><tr><td headers="hd_h_ch6.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Spiegel, D., Boyer, M. J., Hong, J. C., Willaims, C. D., Kelley, M. J., Salama, J. K., Palta, M., Non-operative management for locally advanced rectal cancer in the veterans health administration, International Journal of Radiation Oncology Biology Physics, 99 (2 Supplement 1), S67–S68, 2017
|
|
</td><td headers="hd_h_ch6.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Conference abstract</td></tr><tr><td headers="hd_h_ch6.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Sposato, L. A., Lam, Y., Karapetis, C., Vatandoust, S., Roy, A., Hakendorf, P., Dwyer, A., de Fontgalland, D., Hollington, P., Wattchow, D., Observation of “complete clinical response” in rectal cancer after neoadjuvant chemoradiation: The Flinders experience, Asia-Pacific Journal of Clinical Oncology, 14, 439–445, 2018 [<a href="https://pubmed.ncbi.nlm.nih.gov/29932278" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 29932278</span></a>]
|
|
</td><td headers="hd_h_ch6.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Does not report prognostic analysis</td></tr><tr><td headers="hd_h_ch6.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Torres-Mesa, P. A., Oliveros, R., Mesa, J., Olaya, N., Sanchez, R., Outcomes of the non-surgical management of locally advanced rectal cancer after neoadjuvant treatment. [Spanish], Revista Colombiana de Cancerologia, 18, 109–119, 2014
|
|
</td><td headers="hd_h_ch6.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Spanish language</td></tr><tr><td headers="hd_h_ch6.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Vaccaro, C. A., Yazyi, F. J., Ojra Quintana, G., Santino, J. P., Sardi, M. E., Beder, D., Tognelli, J., Bonadeo, F., Lastiri, J. M., Rossi, G. L., Locally advanced rectal cancer: Preliminary results of rectal preservation after neoadjuvant chemoradiotherapy, Cirugia espanola, 94, 274–9, 2016 [<a href="https://pubmed.ncbi.nlm.nih.gov/26980259" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 26980259</span></a>]
|
|
</td><td headers="hd_h_ch6.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No multivariate prognostic analysis. Univariate data for: initial MRI stage.</td></tr><tr><td headers="hd_h_ch6.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
van der Valk
|
|
M, Hilling
|
|
D, Bastiaannet
|
|
E, et al. Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch & Wait Database (IWWD): an international multicentre registry study, The Lancet, 391, 2537–2545, 2018 [<a href="https://pubmed.ncbi.nlm.nih.gov/29976470" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 29976470</span></a>]
|
|
</td><td headers="hd_h_ch6.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Does not report prognostic analysis</td></tr><tr><td headers="hd_h_ch6.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Vatandoust
|
|
S, Lam
|
|
YH, Roy
|
|
AC, Wattchow
|
|
D, Hollington
|
|
P, Karapetis
|
|
C
|
|
Retrospective study of patients (pts) who were managed with watch and wait strategy (W&W) after neoadjuvant chemoradiation (NCRT) for locally advanced rectal cancer (LARC)., Proc Am Soc Clin Oncol, 33: , 2015
|
|
</td><td headers="hd_h_ch6.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Abstract only</td></tr><tr><td headers="hd_h_ch6.appk.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Vitelli, C. E., Stipa, F., De Paula, U., Is a policy of watch and wait after a complete response following neoadjuvant treatment for locally advanced rectal adenocarcinoma justified? Should we reset the limit?, Updates in surgery, 66, 7–8, 2014 [<a href="https://pubmed.ncbi.nlm.nih.gov/24288010" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 24288010</span></a>]
|
|
</td><td headers="hd_h_ch6.appk.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Expert review</td></tr></tbody></table></div></div></article></div><div id="jr-scripts"><script src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/libs.min.js"> </script><script src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/jr.min.js"> </script></div></div>
|
|
|
|
|
|
|
|
|
|
<!-- Book content -->
|
|
|
|
<script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js"> </script>
|
|
|
|
|
|
<!-- CE8B5AF87C7FFCB1_0191SID /projects/books/PBooks@9.11 portal106 v4.1.r689238 Tue, Oct 22 2024 16:10:51 -->
|
|
<span id="portal-csrf-token" style="display:none" data-token="CE8B5AF87C7FFCB1_0191SID"></span>
|
|
|
|
<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/js/3968615.js" snapshot="books"></script></body>
|
|
</html>
|